

Lyme disease: diagnosis and management

[B] Evidence review for diagnostic accuracy of signs and symptoms

NICE guideline

Intervention evidence review

September 2017

Draft for Consultation

*This evidence review was developed by
the National Guideline Centre*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2017. All rights reserved. Subject to Notice of rights.

ISBN:

Contents

1	Diagnostic accuracy of signs and symptoms for Lyme disease	6
1.1	Review question: In people with suspected (or under investigation for) Lyme disease, how accurate are signs and symptoms to identify whether Lyme disease is present?	6
1.2	Introduction	6
1.3	PICO table.....	6
1.4	Clinical evidence	7
1.4.1	Included studies	7
1.4.2	Excluded studies.....	7
1.4.3	Summary of clinical studies included in the evidence review.....	7
1.4.4	Quality assessment of clinical studies included in the evidence review	14
1.5	Economic evidence	18
1.5.1	Included studies	18
1.5.2	Excluded studies.....	18
1.6	Resource impact	18
1.7	Evidence statements	18
1.7.1	Clinical evidence statements.....	18
1.7.2	Health economic evidence statements.....	19
1.8	Recommendations	19
1.9	Rationale and impact.....	20
1.9.1	Why the committee made the recommendations.....	20
1.9.2	Impact of the recommendations on practice.....	20
1.10	The committee's discussion of the evidence.....	21
1.10.1	Interpreting the evidence.....	21
1.10.2	Cost effectiveness and resource use	23
1.10.3	Other factors the committee took into account	23
	References.....	25
	Appendices.....	32
	Appendix A: Review protocols	32
	Appendix B: Literature search strategies	36
	B.1 Clinical search literature search strategy	36
	B.2 Health Economics literature search strategy.....	38
	Appendix C: Clinical evidence selection.....	43
	Appendix D: Clinical evidence tables	44
	Appendix E: Coupled sensitivity and specificity forest plots and sROC curves.....	75
	E.1.1 Evidence from cohort studies.....	75
	E.1.2 Evidence from case-control studies	75
	E.2 Coupled sensitivity and specificity forest plots (children).....	76

E.2.1 Evidence from cohort studies	76
E.2.2 Evidence from case-control studies	77
Appendix F: Health economic evidence selection	81
Appendix G: Health economic evidence tables	82
Appendix H: Excluded studies.....	83
H.1 Excluded clinical studies.....	83
H.2 Excluded health economic studies.....	85

1 Diagnostic accuracy of signs and symptoms for Lyme disease

1.1 Review question: In people with suspected (or under investigation for) Lyme disease, how accurate are signs and symptoms to identify whether Lyme disease is present?

1.2 Introduction

Lyme disease is the occurrence of symptoms associated with infection with *Borrelia burgdorferi*. The incubation period is variable generally from a few days to 1 month but this can be longer. A circular, target-like rash usually centred on the bite, known as erythema migrans, is considered pathognomonic for Lyme disease but other symptoms are less specific to Lyme disease.

Knowing the diagnostic accuracy of individual signs and symptoms may aid the clinician in making a decision on whether to consider Lyme disease and assist the clinician in carrying out appropriate testing to determine if Lyme disease can safely be ruled out. This section includes the report of an evidence review on diagnostic accuracy and other factors that contributed to the recommendations.

1.3 PICO table

For full details, see the review protocol in appendix A.

Table 1: PICO characteristics of review question

Population	Adults (18 years and over), young people (12 to 17 years) and children (under 12 years) with suspected (or under investigation for) Lyme disease.
Target condition	Lyme disease Specifically, conditions caused by <i>Borrelia burgdorferi sensu lato</i>
Index tests (comparators)	Signs and symptoms: <ul style="list-style-type: none">• acrodermatitis chronica atrophicans (ACA)• erythema migrans (EM)• facial palsy• heart block or arrhythmias• lymphocytoma. <p>The review will assess the accuracy of individual signs and symptoms or any combinations to identify whether Lyme disease is present.</p>
Reference standards	<ul style="list-style-type: none">• <i>Borrelia</i> culture (Spirochaete is difficult to culture, grows slowly, and is therefore not compatible with providing a rapid diagnostic result).• Polymerase chain reaction (PCR)• Clinical diagnosis
Statistical measures	Detecting Lyme disease <ul style="list-style-type: none">• Sensitivity• Specificity• Positive Predictive Value (PPV)• Negative Predictive Value (NPV)

	<ul style="list-style-type: none"> • Receiver Operating Characteristic (ROC) curve or area under curve
Study design	<p>Include:</p> <ul style="list-style-type: none"> • Cross-sectional studies, in which the index test(s) and the reference standard test are applied to the same people <p>Exclude (unless there is insufficient evidence and agreed to include with committee):</p> <ul style="list-style-type: none"> • Two-gate/case-control study designs that compare the results of the index test in people with an established diagnosis with its results in healthy controls. <p>Exclude:</p> <ul style="list-style-type: none"> • Case series • Case reports

1 Some of the more non-specific signs and symptoms such as fever, fatigue, and headache
 2 were not included in the evidence review because the guideline committee agreed to
 3 prioritise more clearly defined signs and symptoms as evidence was more likely to be found
 4 for these.

5 1.4 Clinical evidence

6 1.4.1 Included studies

7 Sixteen studies were included in the review.^{5,6,17,34,37,41,43,45,60,67,69,70,76,79,80,86} These are
 8 summarised in Table 2 below. Seven studies were in adults^{5,17,34,37,41,60,79} and 9 studies
 9 were in children.^{6,43,45,67,69,70,76,80,86} Evidence from these studies is summarised in the
 10 clinical evidence summary below (Table 3).

11 See also the study selection flow chart in appendix C, sensitivity and specificity forest plots
 12 and receiver operating characteristics (ROC) curves in appendix E, and study evidence
 13 tables in appendix D.

14 No cross-sectional diagnostic accuracy studies were identified. The majority of the included
 15 studies were not designed with the aim of determining the diagnostic accuracy of signs and
 16 symptoms. Most included studies were cohort and case-control studies aiming to
 17 characterise Lyme disease patients, study patient outcomes, or report the incidence of Lyme
 18 disease among those investigated. For the purposes of this review, where studies reported
 19 the proportions of positive and negative Lyme disease cases with the pre-specified signs or
 20 symptoms, this data was used to determine the diagnostic accuracy. As cohort studies are
 21 considered to be of higher quality than case-control studies, separate analyses were
 22 conducted.

23 1.4.2 Excluded studies

24 See the excluded studies list in appendix H.

25 1.4.3 Summary of clinical studies included in the evidence review

26 **Table 2: Summary of studies included in the evidence review**

Study	Population	Target condition	Index test (sign or symptom)	Reference standard	Comments
Aucott 2009 ⁵	n=165	Lyme disease	Erythema migrans	Centers for disease control and	Retrospective cohort study

Study	Population	Target condition	Index test (sign or symptom)	Reference standard	Comments
	<p>People presenting for possible early Lyme disease</p> <p>Age: not reported</p>			prevention (CDC) case definition confirmed/probable	
Avery 2005 ⁶	<p>n=108</p> <p>Children presenting to hospital with Lyme serology and Lyme CSF-PCR performed during the same hospital encounter</p> <p>Age, mean (range): Lyme meningitis 9 years (2.7-13), aseptic meningitis 9.6 years (3.1-17.8)</p>	Lyme disease	Erythema migrans	CDC criteria (EM or positive serology including Western blot confirmation)	<p>Retrospective cohort study</p> <p>EM (index test) formed part of the criteria for the reference standard</p>
Engervall 1995 ¹⁷	<p>n=446</p> <p>People with acute peripheral facial palsy</p> <p>Age, median (range): borreliosis people 38 years (4-82), no <i>Borrelia</i> infection 49 years (3-88)</p>	Lyme disease	Facial palsy (complete facial palsy)	<p>One or more of the following: serum antibody titres >1,000 in IgG ELISA or >1,500 in IgM ELISA, serum antibody titres of 500-1,000 in IgG ELISA and/ 800-1,500 in IgM ELISA if at least 2-fold increase in titres between 2 examinations, CSF <i>Borrelia</i> antibody titres >8 in IgG ELISA or >10 in IgM ELISA, recent history of presence of typical <i>Borrelia</i> skin manifestations</p>	<p>Prospective cohort study</p> <p>Index test was complete facial palsy rather than presence/absence of facial palsy.</p> <p>423 adults, 23 children</p>
Lipsker 2001 ³⁴	<p>n=132</p> <p>Adults examined for suspected Lyme borreliosis</p> <p>Age, mean</p>	Lyme disease	Erythema migrans	Culture or PCR	<p>Prospective cohort study</p> <p>All 132 people had a clinical diagnosis of Lyme disease according to US</p>

Study	Population	Target condition	Index test (sign or symptom)	Reference standard	Comments
	(range): 54 years (15-92)				epidemiological case definitions for Lyme borreliosis, 41 of these had the culture/PCR testing
Nadelmann 1990 ³⁷	n=104 People who had an illness compatible with Lyme disease Age, range: culture positive people 16-63 years, culture negative people not reported	Lyme disease	Erythema migrans Facial palsy	Culture from blood samples	Prospective cohort study
Ogrinc 2008 ⁴¹	n=339 People with suspected Lyme disease Age, median (range): 53 years (15-81)	Lyme disease	Facial palsy (cranial nerve involvement)	Serological evidence of Lyme disease: serum dilutions of 1:256 or higher interpreted as positive	Prospective cohort study Exclusion of people with current erythema migrans 30.1% of people had already been treated when they received the evaluation Indirectness: cranial nerve involvement used as index test rather than facial palsy
Peltomaa 1998 ⁴³	n=49 Paediatric cases of acute peripheral facial palsy Age, mean: 9.1 years	Lyme disease	Erythema migrans	At least 1 of the following: positive levels of serum/CSF antibodies against <i>B. burgdorferi</i> , EM in the history of the people or concomitantly with facial palsy, positive PCR test	Prospective cohort study EM (index test) formed part of the criteria for the reference standard

Study	Population	Target condition	Index test (sign or symptom)	Reference standard	Comments
Pikelj-Pecnik 2002 ⁴⁵	n=147 cases, 148 controls Children with typical EM (cases) and healthy children of comparable ages and gender distribution (controls) Age, mean (SE): people 5.74 years (3.13), controls 5.68 (3.18)	Lyme disease	Arrhythmia	EM (diagnosis established clinically according to modified CDC criteria)	Case-control study
Sangha 1998 ⁶⁰	n=176 cases, 160 controls Adults who reported a previous diagnosis of Lyme disease/history of a positive result on a serologic test for <i>B. burgdorferi</i> (cases) and adults who reported no history of Lyme disease, with or without symptoms suggestive of previous Lyme disease (controls) Age, mean: cases 47.8 years, controls 49.7 years	Lyme disease	Heart block/arrhythmia (bradycardia, tachycardia, non-sinus rhythm, first-degree atrioventricular block, any bundle-branch block)	CDC case definition: EM (>5cm) or laboratory confirmation of infection and at least 1 late manifestation	Case control study
Shah 2005 ⁶⁷	n=175 Children with Lyme or enteroviral meningitis Age, median	Lyme disease	Erythema migrans Facial palsy	Serological evidence of Lyme disease, CSF pleocytosis, negative CSF bacterial culture, and absence of virus detectable by CSF culture or PCR	Prospective cohort study

Study	Population	Target condition	Index test (sign or symptom)	Reference standard	Comments
	(range): Lyme disease: 10.5 years (4.1-16.9); enteroviral: 5.5 years (0-17.2)				
Skogman 2008 ⁶⁹	n=354 Children referred for evaluation of clinically suspected neuroborreliosis including a lumbar puncture (cases), random sample of Swedish population from the Swedish national register of statistics (controls) Age, median (range): confirmed neuroborreliosis 6 years (1-14), possible neuroborreliosis 7 years (1-18), not determined 12 years (2-18), controls were matched for age	Lyme disease	EM or lymphocytoma Facial palsy	Confirmed: pleocytosis in CSF, <i>Borrelia</i> antibodies in CSF. Possible: pleocytosis in CSF, no <i>Borrelia</i> antibodies in CSF, may have <i>Borrelia</i> antibodies in serum. Not determined: no pleocytosis in CSF, no <i>Borrelia</i> antibodies in CSF, may have antibodies in serum	Prospective cohort/case-control study 82 additional children evaluated for neuroborreliosis during the same period but not asked to participate – no explanation given. People categorised as 'possible neuroborreliosis' not included in the analysis; 'not determined' used as disease controls.
Skogman 2015 ⁷⁰	n=239 Children being evaluated for neuroborreliosis and children being evaluated and diagnosed with other infectious immunological and neurological diseases (controls) Age, median (range):	Lyme disease	NeBoP score (3 or more of the following: facial palsy, fever, fatigue, EM/lymphocytoma, pleocytosis in CSF)	European guidelines: definite and possible neuroborreliosis based on neurological symptoms and laboratory findings in CSF	Mixed methods: retrospective cohort/case-control study Calculations based on 'definite' and 'possible' Lyme neuroborreliosis as positive cases and 'non-Lyme neuroborreliosis' and 'controls' as

Study	Population	Target condition	Index test (sign or symptom)	Reference standard	Comments
	children evaluated for Lyme disease 10 years (1-19), controls 10 years (0-19)				controls Indirectness: index test included fever, fatigue and pleocytosis in CSF
Sundin 2012 ⁷⁶	n=124 Children with neurological complaints Age, median (range): neuroborreliosis 6.7 years (2-15), TBE 8.7 years (3-17), no tick-borne central nervous system (CNS) infection 9 years (1-17)	Lyme disease	Facial palsy	Positive anti- <i>Borrelia</i> IgM or an increased titre (≥ 4 -fold) of anti- <i>Borrelia</i> IgG between acute and convalescent samples	Prospective cohort study 'Other diagnoses' group included 3 cutaneous borreliosis
Tjernberg 2011 ⁷⁹	n=261 People investigated for suspected Lyme neuroborreliosis Age, range: 2-87 years	Lyme disease	Facial palsy (cranial nerve palsy)	European Federation of Neurological Societies guidelines (CSF anti- <i>Borrelia</i> anti-bodies and presence of pleocytosis)	Retrospective cohort study Definite Lyme neuroborreliosis and non-Lyme neuroborreliosis groups used in analysis, possible Lyme neuroborreliosis group excluded
Tveitnes 2012 ⁸⁰	n=211 Children with CSF pleocytosis Age, median (interquartile range): Lyme meningitis 6 years (5-8), bacterial meningitis 3 years (0-6), non-Lyme aseptic	Lyme disease	Erythema migrans Facial palsy	Confirmed Lyme meningitis: neurological symptoms suggestive of neuroborreliosis without other obvious reasons, intrathecal <i>B. burgdorferi</i> antibody production/ Probable Lyme meningitis: neurological symptoms suggestive of neuroborreliosis without other obvious	Retrospective cohort study People group included 91 with confirmed and 51 with probable Lyme disease. Six from the disease control group were not included in the analysis

Study	Population	Target condition	Index test (sign or symptom)	Reference standard	Comments
	meningitis 7 years (3.5-9)			reasons, <i>B. burgdorferi</i> antibody in serum and/or EM	
Waespe 2010 ⁸⁶	n=181 Children hospitalised with clinical signs of aseptic meningitis and/or peripheral facial nerve palsy Age, range: 20 months to 16 years	Lyme disease	Facial palsy	Evidence of intrathecal synthesis of <i>B. burgdorferi</i> antibodies in CSF (confirmed) or in serum or CSF, both confirmed by immunoblot (probable)	Retrospective cohort study Index test positive people were those with facial palsy and those with facial palsy plus aseptic meningitis. 159/181 people were tested for Lyme disease.

1 See appendix D for full evidence tables.

2

3

1 **1.4.4 Quality assessment of clinical studies included in the evidence review**

2 **Table 3: Clinical evidence summary: diagnostic accuracy of signs and symptoms in adults (cohort studies)**

Index Test	Number of studies	n	Quality	Sensitivity % (95% CI)	Specificity % (95% CI)
Erythema migrans					
	3	310	VERY LOW ^{1,2} due to very serious risk of bias, very serious imprecision	Pooled ⁴ : 0.67 [0.21-0.94]	Pooled ⁴ : 0.88 [0.52-0.99]
Facial palsy					
	1	104	VERY LOW ^{1,2} due to very serious risk of bias, very serious imprecision	0.29 [0.04-0.71]	0.96 [0.90-0.99]
	1	216	VERY LOW ^{1,3} due to very serious risk of bias, serious indirectness	0.52 [0.42-0.61]	0.86 [0.77-0.92]
Complete facial palsy					
	1	399	VERY LOW ^{1,2} due to very serious risk of bias, serious imprecision	0.20 [0.07-0.41]	0.69 [0.64-0.74]
Cranial nerve involvement					
	1	278	VERY LOW ^{1,3} due to very serious risk of bias, serious indirectness	0.00 [0.00-0.05]	0.98 [0.95-0.99]

3 *The assessment of the evidence quality was conducted with emphasis on test sensitivity as the committee identified this as the primary measure in guiding decision-making.*

- 4 1 *Risk of bias was assessed using the QUADAS-2 checklist. The evidence was downgraded by 1 increment if the majority of studies were rated at high risk of bias and*
5 *downgraded by 2 increments if the majority of studies were rated at very high risk of bias*
6 2 *Imprecision was assessed based on inspection of the confidence region of sensitivity in the diagnostic meta-analysis or, where diagnostic meta-analysis has not been*
7 *conducted, assessed according to the range of confidence intervals in the individual studies. The evidence was downgraded by 1 increment when the range of the*
8 *confidence interval around the point estimate was 40%, and downgraded by 2 increments when there was a range of >40%*
9 3 *Indirectness was assessed using the QUADAS-2 checklist items referring to applicability. The evidence was downgraded by 1 increment if the majority of studies were*
10 *seriously indirect and downgraded by 2 increments if the majority of studies are very seriously indirect*
11 4 *Pooled sensitivity/specificity from diagnostic meta-analysis. One was added to 0 values in order to calculate a pooled estimate*

Table 4: Clinical evidence summary: diagnostic accuracy of signs and symptoms in adults (case-control studies)

Index Test	Number of studies	n	Quality	Sensitivity % (95% CI)	Specificity % (95% CI)
Heart block/arrhythmias					
Bradycardia	1	336	VERY LOW ¹ due to very serious risk of bias	0.05 [0.02-0.09]	0.98 [0.95-1.00]
Tachycardia	1	336	VERY LOW ¹ due to very serious risk of bias	0.00 [0.00-0.02]	1.00 [0.98-1.00]
Nonsinus rhythm	1	336	VERY LOW ¹ due to very serious risk of bias	0.01 [0.00-0.04]	0.97 [0.93-0.99]
First-degree atrioventricular block	1	336	VERY LOW ¹ due to very serious risk of bias	0.10 [0.06-0.15]	0.95 [0.90-0.98]
Any bundle-branch block	1	336	VERY LOW ¹ due to very serious risk of bias	0.16 [0.11-0.23]	0.84 [0.78-0.90]

The assessment of the evidence quality was conducted with emphasis on test sensitivity as this was identified by the committee as the primary measure in guiding decision-making.

1 Risk of bias was assessed using the QUADAS-2 checklist. The evidence was downgraded by 1 increment if the majority of studies were rated at high risk of bias and downgraded by 2 increments if the majority of studies were rated at very high risk of bias

Table 5: Clinical evidence summary: diagnostic accuracy of signs and symptoms in children (cohort studies)

Index Test	Number of studies	n	Quality	Sensitivity % (95% CI)	Specificity % (95% CI)
Erythema migrans					
	4	537	VERY LOW ^{1,2} due to very serious risk of bias, very serious imprecision	Pooled ⁴ 0.40 [0.15-0.71]	Pooled ⁴ 0.99 [0.96-1.00]
Facial palsy					
	4	653	VERY LOW ^{1,2} due to very serious risk of bias, very serious imprecision	Pooled ⁴ 0.56 [0.24-0.84]	Pooled ⁴ 0.92 [0.69-0.99]
Facial palsy (TBE controls)	1	105	VERY LOW ^{1,2} due to very serious risk of bias,	0.43 [0.22-0.66]	1.00 [0.96-1.00]

Index Test	Number of studies	n	Quality	Sensitivity % (95% CI)	Specificity % (95% CI)
Neuroborreliosis prediction test (NeBoP) score					
3 or more of the following: facial palsy, fever, fatigue, EM, lymphocytoma, pleocytosis in CSF indicates high probability of Lyme neuroborreliosis	1	239	VERY LOW ^{1,3} due to very serious risk of bias, serious indirectness	0.90 [0.82-0.96]	0.90 [0.85-0.95]

The assessment of the evidence quality was conducted with emphasis on test sensitivity as this was identified by the committee as the primary measure in guiding decision-making.

- 1 Risk of bias was assessed using the QUADAS-2 checklist. The evidence was downgraded by 1 increment if the majority of studies were rated at high risk of bias and downgraded by 2 increments if the majority of studies were rated at very high risk of bias
- 2 Imprecision was assessed based on inspection of the confidence region of sensitivity in the diagnostic meta-analysis or, where diagnostic meta-analysis has not been conducted, assessed according to the range of confidence intervals in the individual studies. The evidence was downgraded by 1 increment when the range of the confidence interval around the point estimate was 20-40%, and downgraded by 2 increments when there was a range of >40%
- 3 Indirectness was assessed using the QUADAS-2 checklist items referring to applicability. The evidence was downgraded by 1 increment if the majority of studies were seriously indirect and downgraded by 2 increments if the majority of studies are very seriously indirect.
- 4 Pooled sensitivity/specificity from diagnostic meta-analysis. One was added to 0 values in order to calculate a pooled estimate

Table 6: Clinical evidence summary: diagnostic accuracy of signs and symptoms in children (case-control studies)

Index Test	Number of studies	n	Quality	Sensitivity % (95% CI)	Specificity % (95% CI)
EM or lymphocytoma					
	1	131	VERY LOW ¹ due to very serious risk of bias	0.18 [0.10-0.29]	0.88 [0.77-0.95]
Facial palsy					
Facial palsy (disease controls)	1	131	VERY LOW ^{1,2} due to very serious risk of bias, serious imprecision	0.60 [0.47-0.71]	0.66 [0.53-0.78]
Facial palsy (healthy controls)	1	246	VERY LOW ^{1,2} due to very serious risk of bias,	0.60 [0.47-0.71]	1.00 [0.98-1.00]

Index Test	Number of studies	n	Quality	Sensitivity % (95% CI)	Specificity % (95% CI)
			serious imprecision		
Arrhythmia					
	1	295	VERY LOW ¹ due to serious risk of bias	0.05 [0.02-0.10]	0.79 [0.72-0.85]

The assessment of the evidence quality was conducted with emphasis on test sensitivity as this was identified by the committee as the primary measure in guiding decision-making.

- 1 Risk of bias was assessed using the QUADAS-2 checklist. The evidence was downgraded by 1 increment if the majority of studies were rated at high risk of bias and downgraded by 2 increments if the majority of studies were rated at very high risk of bias*
- 2 Imprecision was assessed based on inspection of the confidence region of sensitivity in the diagnostic meta-analysis or, where diagnostic meta-analysis has not been conducted, assessed according to the range of confidence intervals in the individual studies. The evidence was downgraded by 1 increment when the range of the confidence interval around the point estimate was 20-40% and downgraded by 2 increments when there was a range of >40%*

1 1.5 Economic evidence

2 1.5.1 Included studies

3 No relevant health economic studies were identified.

4 1.5.2 Excluded studies

5 No health economic studies were identified and excluded.

6 See also the health economic study selection flow chart in appendix F.

7 1.6 Resource impact

8 We do not expect recommendations resulting from this review area to have a significant
9 impact on resources.

10 1.7 Evidence statements

11 1.7.1 Clinical evidence statements

12 Adults and young people:

- 13 • Very Low quality evidence from 3 cohort studies showed a low sensitivity of 67% and
14 a high specificity of 88% for erythema migrans.
- 15 • Very Low quality evidence from 2 cohort studies showed a low sensitivity of 29% and
16 52% and a high specificity of 86% and 96% for facial palsy in general. Very Low
17 quality evidence from 1 cohort study showed a very low sensitivity of 20% and a low
18 specificity of 69% for complete facial palsy. Very Low quality evidence from 1 cohort
19 study found a high specificity of 98% for cranial involvement. Cranial nerve
20 involvement was not suitable as a marker for detecting Lyme disease with a
21 sensitivity of 0%.
- 22 • Very Low quality evidence from 1 case-control study showed a very low sensitivity but
23 high specificity for various cardiac signs and symptoms. Sensitivity for various cardiac
24 signs and symptoms ranged from 0% to 16% and specificity ranged from 84% to
25 100%.

26 Children:

- 27 • Very Low quality evidence from 4 cohort studies showed a low sensitivity of 40% and
28 a high specificity of 99% for erythema migrans.
- 29 • Very Low quality from 1 case-control study showed a very low sensitivity of 18% and
30 a specificity of 88% for erythema migrans or lymphocytoma.
- 31 • Very Low quality evidence from 4 cohort studies showed a low sensitivity of 56% but
32 a high specificity of 92% for facial palsy. Very Low quality evidence from 1 other
33 cohort study, however, found a lower sensitivity of 43% and a higher specificity of
34 100% for facial palsy. Very Low quality evidence from 2 case-control studies showed
35 a low sensitivity of 60% for facial palsy. The specificity was 66% when people with
36 other diseases functioned as controls and 100% when healthy controls were included
37 in the analysis.
- 38 • Very Low quality evidence from 1 study found the NeBoP score, a neuroborreliosis
39 prediction test, to have a high sensitivity of 90% and high specificity of 90%.
- 40 • Very Low quality evidence from 1 case-control study showed a very low sensitivity of
41 5% and a low specificity of 79% for arrhythmias.

1 **1.7.2 Health economic evidence statements**

2 No relevant economic evaluations were identified.

3 **1.8 Recommendations**

4 B1. Diagnose Lyme disease in people with erythema migrans,¹ that is:

- 5 • a red rash, that increases in size and may sometimes have a central clearing
- 6 • not usually itchy, hot or painful
- 7 • usually becomes visible from 1 to 4 weeks (but can appear from 3 days to 3
- 8 months) after exposure and lasts for several weeks
- 9 • usually at the site of the tick bite.

10 B2. Be aware a rash can develop as a reaction to a tick bite, which is not erythema
11 migrans, that:

- 12 • usually develops and recedes over 48 hours from the time of the tick bite
- 13 • may or may not be hot, itchy or painful
- 14 • may be caused by an inflammatory reaction or infection with a common skin
15 pathogen.

16 B3. Consider the possibility of Lyme disease in people presenting with several of the
17 following symptoms, because Lyme disease is a possible but uncommon cause of:

- 18 • flu-like symptoms, such as fever and sweats, swollen glands and fatigue
- 19 • neck pain or stiffness
- 20 • joint or muscle pain
- 21 • cognitive impairment, such as memory problems and difficulty concentrating
22 (sometimes described as 'brain fog')
- 23 • headache
- 24 • paraesthesia.

25 B4. Consider the possibility of Lyme disease in people presenting with symptoms and
26 signs relating to an organ system (focal symptoms) because Lyme disease is a
27 possible but uncommon cause of:

- 28 • neurological symptoms, such as facial palsy or other unexplained cranial nerve
29 palsies, meningitis, mononeuritis multiplex or other unexplained radiculopathy; or
30 rarely encephalitis, neuropsychiatric presentations, or unexplained white matter
31 changes on brain imaging
- 32 • cardiac problems, such as heart block or pericarditis
- 33 • inflammatory arthritis affecting 1 or several joints
- 34 • eye symptoms (less commonly), such as uveitis or keratitis
- 35 • skin rashes resembling erythema migrans, acrodermatitis chronica atrophicans or
36 lymphocytoma.

37 B5. If a person presents with symptoms that suggest the possibility of Lyme disease,
38 explore how long the person has had symptoms and their history of possible tick
39 exposure, for example, ask about:

- 40 • activities that might have exposed them to ticks
- 41 • travel to areas where Lyme disease is known to be prevalent.

¹ See [NHS choices](#) for an image of erythema migrans.

- 1 B6. Do not rule out the possibility of Lyme disease in people with symptoms but no clear
2 history of tick exposure.
- 3 B7. Do not diagnose Lyme disease in people without symptoms, even if they have had a
4 tick bite.
- 5 B8. Be cautious about diagnosing Lyme disease in people without a supportive history or
6 positive testing because of the risk of:
- 7 • missing an alternative diagnosis
8 • providing inappropriate treatment.
- 9 B9. Follow usual clinical practice to manage symptoms, for example pain relief for
10 headaches or muscle pain, in people being assessed for Lyme disease.
- 11 B10. Be aware that people with Lyme disease may have symptoms of cognitive
12 impairment and may have difficulty explaining their symptoms. Follow the
13 recommendations in NICE's guideline on [patient experience in adult NHS services](#).

14 **1.9 Rationale and impact**

15 **1.9.1 Why the committee made the recommendations**

16 Lyme disease has a varied presentation and is uncommon, so it may sometimes be
17 difficult to identify.

18 The diagnostic accuracy of key signs and symptoms of Lyme disease (erythema
19 migrans, facial palsy, lymphocytoma, acrodermatitis chronica atrophicans and heart
20 block or arrhythmias) was reviewed to assess if any could be used to diagnose Lyme
21 disease or to indicate that testing should be carried out.

22 Erythema migrans only occurs in Lyme disease and can be used to diagnose Lyme
23 disease. Some healthcare professionals may not be familiar with erythema migrans, so a
24 description of the rash and its characteristics was included.

25 Erythema migrans is not always present in Lyme disease, and so the assessment of
26 other signs and symptoms is important. The evidence was not strong enough for the
27 committee to recommend diagnosis, testing or treatment based on any other symptom
28 or sign alone. The committee noted a number of potential presentations of Lyme
29 disease, which should prompt a discussion about the possibility of tick exposure. Factors
30 to consider in history and presentation are highlighted to help with clinical decision-
31 making.

32 **1.9.2 Impact of the recommendations on practice**

33 Current practice is to diagnose and treat erythema migrans as Lyme disease. Those
34 who present without erythema migrans, but whose history and presentation is consistent
35 with Lyme disease, receive diagnostic testing. The recommendations will not change
36 current practice but may serve as a reminder to healthcare professionals to think about
37 Lyme disease as a differential diagnosis, particularly in areas where Lyme disease is
38 less common. As a result, the committee did not consider that these recommendations
39 would have a resource impact.

1 1.10 The committee's discussion of the evidence

2 1.10.1 Interpreting the evidence

3 1.10.1.1 The diagnostic measures that matter most

4 Diagnostic accuracy studies where the accuracy of a sign or symptom for Lyme disease
5 was measured against a reference standard (*Borrelia* culture or polymerase chain
6 reaction) were used in this review.

7 The guideline committee identified 5 key clinical signs and symptoms: erythema migrans
8 (EM), lymphocytoma, facial palsy, acrodermatitis chronica atrophicans (ACA), and heart
9 block or arrhythmia. The aim of this review was to assess whether these signs and
10 symptoms, alone or in combination, could be used to identify if a person had Lyme
11 disease. Erythema migrans is only associated with Lyme disease, although not every
12 person with Lyme disease develops an erythema migrans rash. Acrodermatitis chronica
13 atrophicans is associated with Lyme disease, but other types of acrodermatitis can occur
14 as part of other conditions. Lymphocytoma, facial palsy and heart block or arrhythmia
15 are not specific to Lyme disease.

16 Sensitivity was considered the most important measure. The sensitivity of a sign or
17 symptom describes the proportion of positive Lyme disease results that are correctly
18 identified as such. It is the extent to which people with Lyme disease (true positives) are
19 not missed or overlooked. False negatives, those people with Lyme disease who do not
20 have the sign or symptom, are few.

21 The listed signs and symptoms cannot, however, be used to rule out Lyme disease as
22 not all people with Lyme disease develop every sign or symptom. Specificity, the
23 proportion of negative Lyme disease results that are correctly identified as such, is of
24 less use than sensitivity.

25 1.10.1.2 The quality of the evidence

26 Thirteen cohort studies comprising 2,534 children and adults and 3 case-control studies
27 comprising 677 children and adults were included in this review. The evidence was of
28 very low quality because of risk of bias, imprecision and indirectness. There were
29 particular concerns about how the signs and symptoms were described and assessed as
30 well as the inadequate reference standard (culture, PCR or clinical diagnosis in the
31 absence of a gold standard), that is, how Lyme disease was determined.

32 Evidence derived from case-control studies could potentially be an overestimate of the
33 true sensitivity and specificity values. Populations in case-control studies tend to differ
34 from 'true populations' found in clinical practice as cases tend to be more severely ill
35 than the average patient population in clinical practice. Controls are usually drawn from
36 a healthy population or include known specific cross-reactivity controls. Therefore,
37 evidence from case-control studies started at low quality and could be further
38 downgraded according to issues of risk of bias, imprecision and indirectness.

39 1.10.1.3 Benefits and harms

40 1.10.1.3.1 *Acrodermatitis chronica atrophicans* (ACA)

41 No evidence for acrodermatitis chronica atrophicans was identified. The guideline
42 committee were aware of ACA as a possible symptom of Lyme disease and considered
43 the potential harm of missing a Lyme disease diagnosis if ACA is not recognised as
44 such. It was therefore decided to recommend that the possibility of Lyme disease be
45 considered in those presenting with ACA.

11.10.1.3.2 *Erythema migrans (EM)*

2 Pooled evidence from 3 cohort studies showed a low sensitivity for erythema migrans in
3 children and adults. Sensitivity of the rash was lower in children than in adults, with 40%
4 and 67%, respectively. Specificity was high, with 99% and 88% in children and adults
5 respectively. The evidence showing high specificity supported current practice to
6 diagnose and treat EM as Lyme disease. The guideline committee considered that the
7 potential harm of Lyme disease dissemination if this was to change and therefore
8 decided to recommend diagnosis of Lyme disease in people with EM, despite the low
9 quality of the evidence.

101.10.1.3.3 *Facial palsy*

11 The evidence showed a low sensitivity but high specificity for facial palsy in children and
12 adults. In adults, evidence from 2 cohort studies showed that facial palsy had a
13 sensitivity of 29% and 52%, and a specificity of 96% and 86%. Pooled evidence from
14 cohort studies in children showed a sensitivity of 56% and a specificity of 92%. Evidence
15 from 1 case-control study in children showed a sensitivity of 60%, with a specificity of
16 66% and 100% for disease controls and healthy controls, respectively.

17 There was a high degree of variability in the degree and type of facial palsy. A cohort
18 study in adults who all had an acute peripheral facial palsy showed that a complete facial
19 palsy had a sensitivity of 20% and a specificity of 69%. Another cohort study assessing
20 the accuracy of any kind of cranial nerve involvement in diagnosing Lyme disease in
21 adults resulted in a sensitivity of 0%, indicating that none of the people with Lyme
22 disease in this study had cranial nerve involvement and a specificity of 98%.

23 The guideline committee did not consider the evidence to be strong enough to
24 recommend diagnosis of Lyme disease based on facial palsy alone. It did, however,
25 acknowledge the evidence of high specificity and the potential harm of missing a Lyme
26 disease diagnosis if facial palsy is not considered as a possible symptom. It was
27 therefore decided to recommend that the possibility of Lyme disease be considered in
28 those presenting with facial palsy.

291.10.1.3.4 *Heart block or arrhythmia*

30 The limited evidence showed a very low sensitivity of 0%-16% and a high specificity for
31 heart block or arrhythmia in adults and a sensitivity of 5% for arrhythmia only in children.

32 The guideline committee did not consider the evidence to be strong enough to
33 recommend diagnosis of Lyme disease based on heart block or arrhythmia alone. It did,
34 however, acknowledge the evidence of high specificity and the potential harm of missing
35 a Lyme disease diagnosis if heart block and arrhythmia are not considered as possible
36 symptoms. It was therefore decided to recommend that the possibility of Lyme disease
37 be considered in those presenting with heart block or arrhythmia.

381.10.1.3.5 *Lymphocytoma*

39 No evidence for lymphocytoma alone was identified. Evidence from 1 case-control study
40 in children showed a very low sensitivity of 18% and a specificity of 88% for either an
41 erythema migrans rash or a lymphocytoma.

42 The guideline committee did not consider the evidence to be strong enough to
43 recommend diagnosis of Lyme disease based on a lymphocytoma alone. It did,
44 however, acknowledge the evidence of high specificity and the potential harm of missing
45 a Lyme disease diagnosis if lymphocytoma is not considered as a possible symptom. It
46 was therefore decided to recommend that the possibility of Lyme disease be considered
47 in those presenting with a lymphocytoma.

11.10.1.3.6 **Other measures**

2 One study in children assessed the diagnostic accuracy of the NeBoP score, a weighted
3 score derived from facial palsy, fever, fatigue, erythema migrans or lymphocytoma, and
4 pleocytosis in CSF. Designed to differentiate between a high and low probability of
5 having neuroborreliosis, the NeBoP has a maximum score of 5 points. A score of 3 or
6 more of these variables had a sensitivity of 90% and a specificity of 90%. The guideline
7 committee agreed that the score seemed promising in terms of its high sensitivity and
8 specificity relative to the other individual signs and symptoms. However, the committee
9 considered that the quality and quantity of the evidence available was too low to make a
10 recommendation for its use.

11 **1.10.2 Cost effectiveness and resource use**

12 No health economic evidence was identified. Assessment of the signs and symptoms is
13 unlikely to be an additional cost to the NHS, as these people will be assessed anyway.
14 These signs and symptoms, however, will help to identify the population that should be
15 considered for testing or empiric treatment.

16 The diagnostic evidence showed that where accuracy data was available all symptoms
17 had high specificity and low sensitivity, which means that false positives are few but
18 false negatives are high. As a result, few people who do not have Lyme disease are
19 identified as having Lyme disease, but many people with Lyme disease will be missed.

20 The committee agreed to recommend diagnosis of Lyme disease based on EM alone
21 (no diagnostic testing), as it is considered pathognomonic for Lyme disease. This is
22 already done in current practice and so should have no impact on NHS resources.

23 The committee, however, noted that the evidence was not strong enough to recommend
24 further diagnostic testing or diagnosis and treatment based on the presentation of any of
25 the other symptoms alone. The committee noted the importance of considering the
26 possibility of Lyme disease if a number of these symptoms are accompanied by
27 supportive history of tick exposure. These recommendations are not expected to have a
28 resource impact.

29 **1.10.3 Other factors the committee took into account**

30 While erythema migrans is considered pathognomonic for Lyme disease, the committee
31 considered that it might be unfamiliar to some healthcare professionals, so a
32 recommendation describing the rash and its characteristics was developed. The
33 committee also developed a recommendation to describe an inflammatory reaction to a
34 tick bite in case this was mistaken for erythema migrans.

35 The committee used the evidence review and their knowledge of presentations of Lyme
36 disease to develop recommendations for possible presentations associated with Lyme
37 disease. The committee acknowledged that some non-specific symptoms associated
38 with Lyme disease are difficult to describe; for example, a cognitive impairment such as
39 the difficulty of remembering what a person has just read is often described as 'brain
40 fog'. Clinicians should also be aware that persons with cognitive impairment might find it
41 difficult to describe their symptoms. The committee felt that it was important to include an
42 awareness of these non-specific signs and symptoms in the recommendations because
43 although Lyme disease would not be diagnosed based on them alone, they can be
44 valuable in the context of other symptoms and history of exposure.

45 The committee acknowledged that most people presenting with symptoms or signs
46 associated with Lyme disease will not have Lyme disease. Lyme disease is a possible
47 but uncommon cause of these symptoms. The majority of people presenting with
48 arrhythmia, for example, would not require testing for Lyme disease, as there would be

1 more likely causes to investigate. An exploration of the history of symptoms and possible
2 exposure to ticks is required, but a lack of clear history of tick bite should not rule out the
3 further investigation. Clinical judgement of the presentation with awareness of Lyme
4 disease as a possible cause is required.

5 The committee expressed the need for evidence on the proportion of individual signs
6 and symptoms in which Lyme disease is the possible underlying cause. For example,
7 knowing the proportion of facial palsies that are caused by Lyme disease could provide a
8 better understanding of different clinical presentations of Lyme disease and therefore
9 help guide clinical decision-making. This information could be collected through the
10 recommendation for research on the clinical epidemiology of Lyme disease.

11 While there is concern that Lyme disease may be missed, the committee also
12 recognised the harm that might be done by missing an alternative diagnosis or providing
13 inappropriate treatment. The committee considered that an acknowledgement that
14 symptoms and signs associated with Lyme disease are similar to symptoms or signs of
15 many other disorders and that no specific medical cause might be found for some
16 symptoms might be helpful for people undergoing investigation.

17 Signs and symptoms of Lyme disease in children were considered, but the committee
18 did not think separate recommendations were warranted. Fever in children during the
19 summer months when respiratory infections are less common was identified as a
20 circumstance when Lyme disease in children might be more likely when associated with
21 a relevant clinical history. While the committee wished all clinicians to be aware of
22 possible presentations of Lyme disease they considered that children and young people
23 (younger than 18 years) who are presenting with possible Lyme disease and non-EM,
24 for example facial palsy, should have their diagnosis and management discussed with a
25 specialist, as these presentations are unusual and the importance of accurate diagnosis
26 and treatment is essential. This is discussed further in evidence report D.

References

1. Afari ME, Marmoush F, Rehman MU, Gorski U, Yammine JF. Lyme carditis: an interesting trip to third-degree heart block and back. *Case Reports in Cardiology*. 2016; 2016:5454160
2. Ahmed A. When is facial paralysis Bell palsy? current diagnosis and treatment. *Cleveland Clinic Journal of Medicine*. 2005; 72(5):398-405
3. Arnez M, Pleterski-Rigler D, Luznik-Bufon T, Ruzic-Sabljić E, Strle F. Solitary and multiple erythema migrans in children: comparison of demographic, clinical and laboratory findings. *Infection*. 2003; 31(6):404-409
4. Asbrink E, Olsson I, Hovmark A. Erythema chronicum migrans Afzelius in Sweden. A study on 231 patients. *Zentralblatt für Bakteriologie, Mikrobiologie, und Hygiene - Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology*. 1986; 263(1-2):229-236
5. Aucott J, Morrison C, Munoz B, Rowe PC, Schwarzwald A, West SK. Diagnostic challenges of early Lyme disease: lessons from a community case series. *BMC Infectious Diseases*. 2009; 9:79
6. Avery RA, Frank G, Eppes SC. Diagnostic utility of *Borrelia burgdorferi* cerebrospinal fluid polymerase chain reaction in children with Lyme meningitis. *Pediatric Infectious Disease Journal*. 2005; 24(8):705-708
7. Bartunek P, Zapletalova J, Gorican K, Veselka J, Mrazek V, Nemeč J et al. Lyme carditis. *Sbornik Lekarsky*. 1995; 96(3):199-207
8. Biese KJ, Brown DF, Nadel ES. Heart block and rash. *Journal of Emergency Medicine*. 2006; 30(2):215-218
9. Broekhuijsen-van Henten DM, Braun KP, Wolfs TF. Clinical presentation of childhood neuroborreliosis; neurological examination may be normal. *Archives of Disease in Childhood*. 2010; 95(11):910-914
10. Caruso VG. Facial paralysis from Lyme disease. *Otolaryngology - Head and Neck Surgery*. 1985; 93(4):550-553
11. Coumou J, Herkes EA, Brouwer MC, van de Beek D, Tas SW, Casteelen G et al. Ticking the right boxes: classification of patients suspected of Lyme borreliosis at an academic referral center in the Netherlands. *Clinical Microbiology and Infection*. 2015; 21(4):368.e311-368.e320
12. Dillon R, O'Connell S, Wright S. Lyme disease in the UK: clinical and laboratory features and response to treatment. *Clinical Medicine*. 2010; 10(5):454-457
13. Dolbec KW, Higgins GL, Saucier JR. Lyme carditis with transient complete heart block. *The Western Journal of Emergency Medicine*. 2010; 11(2):211-212
14. Doorey AJ, Schneider E, Bacon AE, 3rd. Complete heart block in an adolescent caused by Lyme disease. A common--and reversible--disorder. *Delaware Medical Journal*. 1991; 63(1):13-17
15. Dunand VA, Bretz AG, Suard A, Praz G, Dayer E, Peter O. Acrodermatitis chronica atrophicans and serologic confirmation of infection due to *Borrelia afzelii* and/or *Borrelia garinii* by immunoblot. *Clinical Microbiology and Infection*. 1998; 4(3):159-163

- 1 16. Earl TJ. Cardiac manifestations of Lyme disease. *Medicine and Health, Rhode*
2 *Island*. 2010; 93(11):339-341
- 3 17. Engervall K, Carlsson-Nordlander B, Hederstedt B, Berggren D, Bjerkhoel A,
4 Carlborg A et al. Borreliosis as a cause of peripheral facial palsy: a multi-center
5 study. *Journal of Oto-Rhino-Laryngology and Its Related Specialties*. 1995;
6 57(4):202-206
- 7 18. Esposito S, Baggi E, Villani A, Norbedo S, Pellegrini G, Bozzola E et al.
8 Management of paediatric Lyme disease in non-endemic and endemic areas:
9 data from the registry of the Italian Society for Pediatric Infectious Diseases.
10 *European Journal of Clinical Microbiology and Infectious Diseases*. 2013;
11 32(4):523-529
- 12 19. Fahrner H, Van der Linden SM, Sauvain MJ, Gern L, Zhioua E, Aeschlimann A.
13 The prevalence and incidence of clinical and asymptomatic Lyme borreliosis in a
14 population at risk. *Journal of Infectious Diseases*. 1991; 163(2):305-310
- 15 20. Feder HM, Jr., Whitaker DL. Misdiagnosis of erythema migrans. *American*
16 *Journal of Medicine*. 1995; 99(4):412-419
- 17 21. Felz MW, Chandler FW, Jr., Oliver JH, Jr., Rahn DW, Schriefer ME. Solitary
18 erythema migrans in Georgia and South Carolina. *Archives of Dermatology*.
19 1999; 135(11):1317-1326
- 20 22. Gissler S, Heininger U. *Borrelia lymphocytoma* ("lymphadenosis benigna cutis").
21 *Archives of Disease in Childhood*. 2002; 87(1):12
- 22 23. Goos M. Acrodermatitis chronica atrophicans and malignant lymphoma. *Acta*
23 *Dermato-Venereologica*. 1971; 51(6):457-459
- 24 24. Grandsaerd MJG, Meulenbroeks AA. Lyme borreliosis as a cause of facial palsy
25 during pregnancy. *European Journal of Obstetrics Gynecology and Reproductive*
26 *Biology*. 2000; 91(1):99-101
- 27 25. Halperin J, Luft BJ, Volkman DJ, Dattwyler RJ. Lyme neuroborreliosis: peripheral
28 nervous system manifestations. *Brain*. 1990; 113(4):1207-1221
- 29 26. Hanner P, Edstrom S, Slagsvold P, Kaijser B. Peripheral facial palsy: antibody
30 levels to *Borrelia* in serum and CSF. *Clinical Otolaryngology and Allied Sciences*.
31 1993; 18(5):419-422
- 32 27. Holland NJ, Weiner GM. Recent developments in Bell's palsy. *British Medical*
33 *Journal*. 2004; 329(7465):553-557
- 34 28. Hufschmidt A, Shabarin V, Yakovlev-Leyendecker O, Deppe O, Rauer S.
35 Prevalence of taste disorders in idiopathic and *B. burgdorferi*-associated facial
36 palsy. *Journal of Neurology*. 2009; 256(10):1750-1752
- 37 29. Jenke AC, Stoek LM, Zilbauer M, Wirth S, Borusiak P. Facial palsy: etiology,
38 outcome and management in children. *European Journal of Paediatric*
39 *Neurology*. 2011; 15(3):209-213
- 40 30. Keh SM, Vestey JP, Ho-Yen D, Cain AJ. Ear presentation of Lyme borreliosis in
41 a child. *Journal of Laryngology and Otology*. 2012; 126(11):1176-1178
- 42 31. Kimball SA, Janson PA, LaRaia PJ. Complete heart block as the sole
43 presentation of Lyme disease. *Archives of Internal Medicine*. 1989; 149(8):1897-
44 1898

- 1 32. Kindler W, Wolf H, Thier K, Oberndorfer S. Peripheral facial palsy as an initial
2 symptom of Lyme neuroborreliosis in an Austrian endemic area. *Wiener Klinische*
3 *Wochenschrift*. 2016; 128(21):837-840
- 4 33. Kindstrand E, Nilsson BY, Hovmark A, Pirskanen R, Asbrink E. Peripheral
5 neuropathy in acrodermatitis chronica atrophicans -A late *Borrelia* manifestation.
6 *Acta Neurologica Scandinavica*. 1997; 95(6):338-345
- 7 34. Lipsker D, Hansmann Y, Limbach F, Clerc C, Tranchant C, Grunenberger F et al.
8 Disease expression of Lyme borreliosis in northeastern France. *European*
9 *Journal of Clinical Microbiology and Infectious Diseases*. 2001; 20(4):225-230
- 10 35. Lotric-Furlan S, Cimperman J, Maraspin V, Ruzic-Sabljić E, Logar M, Jurca T et
11 al. Lyme borreliosis and peripheral facial palsy. *Wiener Klinische Wochenschrift*.
12 1999; 111(22-23):970-975
- 13 36. Malane MS, Grant-Kels JM, Feder HM, Jr., Luger SW. Diagnosis of Lyme
14 disease based on dermatologic manifestations. *Annals of Internal Medicine*.
15 1991; 114(6):490-498
- 16 37. Nadelman RB, Pavia CS, Magnarelli LA, Wormser GP. Isolation of *Borrelia*
17 *burgdorferi* from the blood of seven patients with Lyme disease. *American*
18 *Journal of Medicine*. 1990; 88(1):21-26
- 19 38. National Institute for Health and Care Excellence. Developing NICE guidelines:
20 the manual. London. National Institute for Health and Care Excellence, 2014.
21 Available from:
22 <http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20over>
23 [view](http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20over)
- 24 39. Neubert U, Krampitz HE, Engl H. Microbiological findings in erythema
25 (chronicum) migrans and related disorders. *Zentralblatt für Bakteriologie,*
26 *Mikrobiologie, und Hygiene - Series A, Medical Microbiology, Infectious*
27 *Diseases, Virology, Parasitology*. 1986; 263(1-2):237-252
- 28 40. Nigrovic LE, Thompson AD, Fine AM, Kimia A. Clinical predictors of Lyme
29 disease among children with a peripheral facial palsy at an emergency
30 department in a Lyme disease-endemic area. *Pediatrics*. 2008; 122(5):e1080-
31 e1085
- 32 41. Ogrinc K, Ruzic-Sabljić E, Strle F. Clinical assessment of patients with suspected
33 Lyme borreliosis. *International Journal of Medical Microbiology*. 2008; 298(Suppl
34 1):356-360
- 35 42. Oymar K, Tveitnes D. Clinical characteristics of childhood lyme neuroborreliosis
36 in an endemic area of northern Europe. *Scandinavian Journal of Infectious*
37 *Diseases*. 2009; 41(2):88-94
- 38 43. Peltomaa M, Saxen H, Seppala I, Viljanen M, Pyykko I. Paediatric facial paralysis
39 caused by Lyme borreliosis: a prospective and retrospective analysis.
40 *Scandinavian Journal of Infectious Diseases*. 1998; 30(3):269-275
- 41 44. Petersen LR, Sweeney AH, Checko PJ, Magnarelli LA, Mshar PA, Gunn RA et al.
42 Epidemiological and clinical features of 1,149 persons with Lyme disease
43 identified by laboratory-based surveillance in Connecticut. *Yale Journal of*
44 *Biology and Medicine*. 1989; 62(3):253-262
- 45 45. Pikelj-Pecnik A, Lotric-Furlan S, Maraspin V, Cimperman J, Logar M, Jurca T et
46 al. Electrocardiographic findings in patients with erythema migrans. *Wiener*
47 *Klinische Wochenschrift*. 2002; 114(13-14):510-514

- 1 46. Pohl-Koppe A, Wilske B, Weiss M, Schmidt H. *Borrelia lymphocytoma* in
2 childhood. *Pediatric Infectious Disease Journal*. 1998; 17(5):423-426
- 3 47. Puri BK, Shah M, Monro JA, Kingston MC, Julu PO. Respiratory modulation of
4 cardiac vagal tone in Lyme disease. *World Journal of Cardiology*. 2014; 6(6):502-
5 506
- 6 48. Qureshi MZ, New D, Zulqarni NJ, Nachman S. Overdiagnosis and overtreatment
7 of Lyme disease in children. *Pediatric Infectious Disease Journal*. 2002; 21(1):12-
8 14
- 9 49. Randazzo DN, Bisaccia E, Klainer AS. Cardiovascular complications of Lyme
10 disease. *Primary Cardiology*. 1993; 19(4):14-16, 19-20
- 11 50. Ranki A, Aavik E, Peterson P, Schauman K, Nurmilaakso P. Successful
12 amplification of DNA specific for Finnish *Borrelia burgdorferi* isolates in erythema
13 chronicum migrans but not in circumscribed scleroderma lesions. *Journal of*
14 *Investigative Dermatology*. 1994; 102(3):339-345
- 15 51. Rattner H, Rodin HH. *Acrodermatitis atrophicans chronica*. *Archives of*
16 *dermatology and syphilology*. 1948; 57(3):431
- 17 52. Rees DH, Keeling PJ, McKenna WJ, Axford JS. No evidence to implicate *Borrelia*
18 *burgdorferi* in the pathogenesis of dilated cardiomyopathy in the United Kingdom.
19 *British Heart Journal*. 1994; 71(5):459-461
- 20 53. Reid MC, Schoen RT, Evans J, Rosenberg JC, Horwitz RI. The consequences of
21 overdiagnosis and overtreatment of Lyme disease: An observational study.
22 *Annals of Internal Medicine*. 1998; 128(5):354-362
- 23 54. Richier P, Pozzetto-Fernandez I, Rieu V, Crozet M, Pichon M, Khettab F et al.
24 Lyme disease revealed by an atrio-ventricular block. *Annales Francaises de*
25 *Medecine d'Urgence*. 2013; 3(4):259-260
- 26 55. Rijpkema SG, Tazelaar DJ, Molkenboer MJ, Noordhoek GT, Plantinga G,
27 Schouls LM et al. Detection of *Borrelia afzelii*, *Borrelia burgdorferi sensu stricto*,
28 *Borrelia garinii* and group VS116 by PCR in skin biopsies of patients with
29 erythema migrans and *acrodermatitis chronica atrophicans*. *Clinical Microbiology*
30 *and Infection*. 1997; 3(1):109-116
- 31 56. Rose CD, Fawcett PT, Eppes SC, Klein JD, Gibney K, Doughty RA. Pediatric
32 Lyme arthritis: clinical spectrum and outcome. *Journal of Pediatric Orthopaedics*.
33 1994; 14(2):238-241
- 34 57. Rose CD, Fawcett PT, Gibney KM, Doughty RA. The overdiagnosis of Lyme
35 disease in children residing in an endemic area. *Clinical Pediatrics*. 1994;
36 33(11):663-668
- 37 58. Rose CD, Fawcett PT, Singsen BH, Dubbs SB, Doughty RA. Use of Western blot
38 and enzyme-linked immunosorbent assays to assist in the diagnosis of Lyme
39 disease. *Pediatrics*. 1991; 88(3):465-470
- 40 59. Ross SA, Sanchez JL. Dermatology diagnosis. Erythema chronicum migrans
41 (ECM). *Boletin de la Asociacion Medica de Puerto Rico*. 1989; 81(9):339-341
- 42 60. Sangha O, Phillips CB, Fleischmann KE, Wang TJ, Fossel AH, Lew R et al. Lack
43 of cardiac manifestations among patients with previously treated Lyme disease.
44 *Annals of Internal Medicine*. 1998; 128(5):346-353

- 1 61. Santino I, Berlutti F, Pantanella F, Sessa R, del Piano M. Detection of *Borrelia*
2 *burgdorferi* sensu lato DNA by PCR in serum of patients with clinical symptoms
3 of Lyme borreliosis. *FEMS Microbiology Letters*. 2008; 283(1):30-35
- 4 62. Schmidt BL, Aberer E, Stockenhuber C, Klade H, Breier F, Luger A. Detection of
5 *Borrelia burgdorferi* DNA by polymerase chain reaction in the urine and breast
6 milk of patients with Lyme borreliosis. *Diagnostic Microbiology and Infectious*
7 *Disease*. 1995; 21(3):121-128
- 8 63. Schwartz I, Bittker S, Bowen SL, Cooper D, Pavia C, Wormser GP. Polymerase
9 chain reaction amplification of culture supernatants for rapid detection of *Borrelia*
10 *burgdorferi*. *European Journal of Clinical Microbiology and Infectious Diseases*.
11 1993; 12(11):879-882
- 12 64. Scrimenti RJ. Erythema chronicum migrans. *Archives of Dermatology*. 1970;
13 102(1):104-105
- 14 65. Seltzer EG, Gerber MA, Cartter ML, Freudigman K, Shapiro ED. Long-term
15 outcomes of persons with Lyme disease. *JAMA*. 2000; 283(5):609-616
- 16 66. Seltzer EG, Shapiro ED. Misdiagnosis of Lyme disease: when not to order
17 serologic tests. *Pediatric Infectious Disease Journal*. 1996; 15(9):762-763
- 18 67. Shah SS, Zaoutis TE, Turnquist J, Hodinka RL, Coffin SE. Early differentiation of
19 Lyme from enteroviral meningitis. *Pediatric Infectious Disease Journal*. 2005;
20 24(6):542-545
- 21 68. Sigal LH. Summary of the first 100 patients seen at a Lyme disease referral
22 center. *American Journal of Medicine*. 1990; 88(6):577-581
- 23 69. Skogman BH, Croner S, Nordwall M, Eknefelt M, Ernerudh J, Forsberg P. Lyme
24 neuroborreliosis in children: a prospective study of clinical features, prognosis,
25 and outcome. *Pediatric Infectious Disease Journal*. 2008; 27(12):1089-1094
- 26 70. Skogman BH, Sjowall J, Lindgren PE. The NeBoP score - a clinical prediction
27 test for evaluation of children with Lyme Neuroborreliosis in Europe. *BMC*
28 *Pediatrics*. 2015; 15:214
- 29 71. Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL et al.
30 Clinical characteristics and treatment outcome of early Lyme disease in patients
31 with microbiologically confirmed erythema migrans. *Annals of Internal Medicine*.
32 2002; 136(6):421-428
- 33 72. Smouha EE, Coyle PK, Shukri S. Facial nerve palsy in Lyme disease: evaluation
34 of clinical diagnostic criteria. *American Journal of Otolaryngology*. 1997; 18(2):257-261
- 35 73. Sood SK, Belman AL, Coyle PK, Preston T, Grimson R, Postels D et al. Facial
36 palsy in Lyme disease. *Archives of Pediatrics and Adolescent Medicine*. 1998;
37 152(9):928-929
- 38 74. Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme
39 disease. *JAMA*. 1993; 269(14):1812-1816
- 40 75. Steinberg SH, Strickland GT, Pena C, Israel E. Lyme disease surveillance in
41 Maryland, 1992. *Annals of Epidemiology*. 1996; 6(1):24-29
- 42 76. Sundin M, Hansson ME, Engman ML, Orvell C, Lindquist L, Wide K et al.
43 Pediatric tick-borne infections of the central nervous system in an endemic region
44 of Sweden: a prospective evaluation of clinical manifestations. *European Journal*
45 *of Pediatrics*. 2012; 171(2):347-352

- 1 77. Thompson A, Mannix R, Bachur R. Acute pediatric monoarticular arthritis:
2 distinguishing Lyme arthritis from other etiologies. *Pediatrics*. 2009; 123(3):959-
3 965
- 4 78. Tibbles CD, Edlow JA. Does this patient have erythema migrans? *Journal of the*
5 *American Medical Association*. 2007; 297(23):2617-2627
- 6 79. Tjernberg I, Henningson AJ, Eliasson I, Forsberg P, Ernerudh J. Diagnostic
7 performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-
8 peptide in Lyme neuroborreliosis. *Journal of Infection*. 2011; 62(2):149-158
- 9 80. Tveitnes D, Natas OB, Skadberg O, Oymar K. Lyme meningitis, the major cause
10 of childhood meningitis in an endemic area: a population based study. *Archives*
11 *of Disease in Childhood*. 2012; 97(3):215-220
- 12 81. Tveitnes D, Oymar K. Gender differences in childhood Lyme neuroborreliosis.
13 *Behavioural Neurology*. 2015; Epublication
- 14 82. Tveitnes D, Oymar K, Natas O. Acute facial nerve palsy in children: how often is
15 it Lyme borreliosis? *Scandinavian Journal of Infectious Diseases*. 2007;
16 39(5):425-431
- 17 83. Vegsundvag J, Nordeide J, Reikvam A, Jenum P. Late cardiac manifestation of
18 infection with *Borrelia burgdorferi* (Lyme disease). *British Medical Journal*. 1993;
19 307(6897):173
- 20 84. Von Stedingk LV, Olsson I, Hanson HS, Asbrink E, Hovmark A. Polymerase
21 chain reaction for detection of *Borrelia burgdorferi* DNA in skin lesions of early
22 and late Lyme borreliosis. *European Journal of Clinical Microbiology and*
23 *Infectious Diseases*. 1995; 14(1):1-5
- 24 85. Vrethem M, Widhe M, Ernerudh J, Garpmo U, Forsberg P. Clinical, diagnostic
25 and immunological characteristics of patients with possible neuroborreliosis
26 without intrathecal ig-synthesis against borrelia antigen in the cerebrospinal fluid.
27 *Neurology International*. 2011; 3(1):4-8
- 28 86. Waespe N, Steffen I, Heininger U. Etiology of aseptic meningitis, peripheral facial
29 nerve palsy, and a combination of both in children. *Pediatric Infectious Disease*
30 *Journal*. 2010; 29(5):453-456
- 31 87. Wackers Garritsen BG. Acrodermatitis chronica atrophicans (Morbus Pick
32 Herxheimer). *Dermatologica*. 1974; 148(1):55-56
- 33 88. Weber K, Neubert U. Clinical features of early erythema migrans disease and
34 related disorders. *Zentralblatt für Bakteriologie, Mikrobiologie, und Hygiene -*
35 *Series A: Medical Microbiology, Infectious Diseases, Virology, Parasitology*.
36 1986; 263(1-2):209-228
- 37 89. Wetter DA, Ruff CA. Erythema migrans in Lyme disease. *CMAJ*. 2011;
38 183(11):1281
- 39 90. Wienecke R, Schlupen EM, Zochling N, Neubert U, Meurer M, Volkenandt M. No
40 evidence for *Borrelia burgdorferi*-specific DNA in lesions of localized
41 scleroderma. *Journal of Investigative Dermatology*. 1995; 104(1):23-26
- 42 91. Wise F. Acrodermatitis chronica atrophicans with angiosarcomas. *Archives of*
43 *dermatology and syphilology*. 1946; 53:423

- 1 92. Woolf PK, Lorsung EM, Edwards KS, Li KI, Kanengiser SJ, Ruddy RM et al.
2 Electrocardiographic findings in children with Lyme disease. *Pediatric Emergency*
3 *Care*. 1991; 7(6):334-336
- 4 93. Wormser GP, Agüero-Rosenfeld ME, Cox ME, Nowakowski J, Nadelman RB,
5 Holmgren D et al. Differences and similarities between culture-confirmed human
6 granulocytic anaplasmosis and early Lyme disease. *Journal of Clinical*
7 *Microbiology*. 2013; 51(3):954-958
- 8 94. Younger DS, Orsher S. Lyme neuroborreliosis: preliminary results from an urban
9 referral center employing strict CDC criteria for case selection. *Neurology*
10 *Research International*. 2010; 2010:525206
- 11 95. Zajkowska J, Czupryna P, Pancewicz SA, Kondrusik M, Moniuszko A.
12 *Acrodermatitis chronica atrophicans*. *The Lancet Infectious Diseases*. 2011;
13 11(10):800

Appendices

Appendix A: Review protocols

Table 7: Review protocol for signs and symptoms

Question number: 2

Relevant section of Scope: assessment and diagnosis

Field	Content
Review question	In people with suspected (or under investigation for) Lyme disease, how accurate are signs and symptoms to identify whether Lyme disease is present?
Type of review question	Diagnostic A review of health economic evidence related to the same review question was conducted in parallel with this review. For details, see the health economic review protocol for this NICE guideline.
Objective of the review	To evaluate the accuracy of signs and symptoms in diagnosing Lyme disease and determine if testing is required or if treatment can or should be started without any further testing.
Eligibility criteria – population / disease / condition / issue / domain	Adults (18 years and over), young people (12 to 17 years) and children (under 12 years) with suspected (or under investigation for) Lyme disease. Target condition: Lyme disease (specifically, conditions caused by <i>Borrelia burgdorferi sensu lato</i>)
Eligibility criteria – intervention(s) / exposure(s) / prognostic factor(s)	Signs and symptoms: <ul style="list-style-type: none"> • acrodermatitis chronica atrophicans • erythema migrans • facial palsy • heart block or arrhythmias • lymphocytoma. The review will assess the accuracy of individual signs and symptoms or any combinations to identify whether Lyme disease is present.
Eligibility criteria – comparator(s) / control or reference (gold) standard	<i>Borrelia</i> culture (Spirochaete is difficult to culture, grows slowly and is therefore not compatible with providing a rapid diagnostic result). PCR
Outcomes and prioritisation	<ul style="list-style-type: none"> • Detecting Lyme disease • Sensitivity • Specificity • Positive Predictive Value • Negative Predictive Value • Receiver Operating Characteristic (ROC) curve or area under curve
Eligibility criteria – study design	Include: Cross-sectional studies, in which the index test(s) and the reference standard test are applied to the same people. Exclude (unless there is insufficient evidence and agreed to include

Field	Content
	<p>with committee):</p> <p>Two-gate/case-control study designs that compare the results of the index test in people with an established diagnosis with its results in healthy controls.</p> <p>Exclude:</p> <ul style="list-style-type: none"> • Case series • Case reports
Other inclusion exclusion criteria	<p>Date limits for search: none</p> <p>Language: English only</p> <p>Setting: all settings where NHS care is provided or commissioned</p>
Proposed sensitivity / subgroup analysis, or meta-regression	<p>Stratum:</p> <ul style="list-style-type: none"> • Children (under 12 years); adults and young people (12 years and over) • Timing of symptom presentation less than 6 weeks; 6 weeks to 6 months; over 6 months from tick bite or infection <p>Subgroups (to be investigated if heterogeneity is identified):</p> <ul style="list-style-type: none"> • People who are immunocompromised • People who have been partially treated (are or have been on antibiotics or steroids)
Selection process – duplicate screening / selection / analysis	<p>Studies will be sifted by title and abstract. Potentially significant publications obtained in full text will then be assessed against the inclusion criteria specified in this protocol.</p>
Data management (software)	<ul style="list-style-type: none"> • Sensitivity and specificity will be calculated using Cochrane Review Manager (RevMan5). • Diagnostic meta-analyses will be conducted using WinBUGS14 and graphically presented using RevMan5. • Bibliographies, citations, study sifting and reference management will be managed using EndNote.
Information sources – databases and dates	<p>Clinical searches Medline, Embase, The Cochrane Library all years</p> <p>Health economic searches Medline, Embase, NHS Economic Evaluation Database (NHS EED), Health Technology Assessment (HTA) all years</p>
Identify if an update	Not applicable
Author contacts	https://www.nice.org.uk/guidance/indevelopment/gid-ng10007
Highlight if amendment to previous protocol	For details, please see section 4.5 of Developing NICE guidelines: the manual.
Search strategy – for one database	For details, please see appendix B
Data collection process – forms / duplicate	A standardised evidence table format will be used, and published as appendix D of the evidence report.
Data items – define all variables to be collected	For details, please see evidence tables in appendix D (clinical evidence tables) or H (health economic evidence tables).
Methods for assessing bias at outcome / study level	<p>Standard study checklists were used to appraise individual studies critically. For details please see section 6.2 of Developing NICE guidelines: the manual</p> <p>The risk of bias will be evaluated for each outcome on a study level using the QUADAS-2 checklist.</p>
Criteria for quantitative	For details, please see section 6.4 of Developing NICE guidelines: the

Field	Content
synthesis	manual.
Methods for quantitative analysis – combining studies and exploring (in)consistency	For details, please see the separate Methods report for this guideline.
Meta-bias assessment – publication bias, selective reporting bias	For details, please see section 6.2 of Developing NICE guidelines: the manual.
Confidence in cumulative evidence	For details, please see sections 6.4 and 9.1 of Developing NICE guidelines: the manual. The quality of the evidence per outcome across studies will be assessed using an adapted GRADE approach.
Rationale / context – what is known	For details, please see the introduction to the evidence review.
Describe contributions of authors and guarantor	A multidisciplinary committee developed the evidence review. The committee was convened by the National Guideline Centre (NGC) and chaired by Saul Faust in line with section 3 of Developing NICE guidelines: the manual. Staff from the NGC undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the evidence review in collaboration with the committee. For details, please see Developing NICE guidelines: the manual.
Sources of funding / support	The NGC is funded by NICE and hosted by the Royal College of Physicians.
Name of sponsor	The NGC is funded by NICE and hosted by the Royal College of Physicians.
Roles of sponsor	NICE funds NGC to develop guidelines for those working in the NHS, public health and social care in England.
PROSPERO registration number	Not registered

1

Table 8: Health economic review protocol

Review question	All questions – health economic evidence
Objectives	To identify health economic studies relevant to any of the review questions.
Search criteria	<ul style="list-style-type: none"> • Populations, interventions and comparators must be as specified in the clinical review protocol above. • Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis). • Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.) • Unpublished reports will not be considered unless submitted as part of a call for evidence. • Studies must be in English.
Search strategy	A health economic study search will be undertaken using population-specific terms and a health economic study filter – see appendix B below.
Review strategy	Studies not meeting any of the search criteria above will be excluded. Studies published before 2001, abstract-only studies and studies from non-OECD countries or the US will also be excluded.

Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).³⁸

Inclusion and exclusion criteria

- If a study is rated as both 'Directly applicable' and with 'Minor limitations', then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.
- If a study is rated as either 'Not applicable' or with 'Very serious limitations', then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.
- If a study is rated as 'Partially applicable' with 'Potentially serious limitations' or both, then there is discretion over whether it should be included.

Where there is discretion

The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to exclude the remaining studies selectively. All studies excluded based on applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.

The health economist will be guided by the following hierarchies.

Setting:

- UK NHS (most applicable).
- OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).
- OECD countries with predominantly private health insurance systems (for example, Switzerland).
- Studies set in non-OECD countries or in the US will be excluded before being assessed for applicability and methodological limitations.

Health economic study type:

- Cost–utility analysis (most applicable).
- Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).
- Comparative cost analysis.
- Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.

Year of analysis:

- The more recent the study, the more applicable it will be.
- Studies published in 2001 or later but that depend on unit costs and resource data entirely or predominantly before 2001 will be rated as 'Not applicable'.
- Studies published before 2001 will be excluded before being assessed for applicability and methodological limitations.

Quality and relevance of effectiveness data used in the health economic analysis:

- The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.

Appendix B: Literature search strategies

The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual 2014, updated 2017 <https://www.nice.org.uk/guidance/pmg20/resources/developing-nice-guidelines-the-manual-pdf-72286708700869>

For more detailed information, please see the Methodology Review.

B.1 Clinical search literature search strategy

The search for this review was constructed using population terms. An excluded studies filter was applied where appropriate.

Table 9: Database date parameters and filters used

Database	Dates searched	Search filter used
Medline (OVID)	1946 – 03 July 2017	Exclusions
Embase (OVID)	1974 – 03 July 2017	Exclusions
The Cochrane Library (Wiley)	Cochrane Reviews to 2017 Issue 7 of 12 CENTRAL to 2017 Issue 6 of 12 DARE, and NHSEED to 2015 Issue 2 of 4 HTA to 2016 Issue 4 of 4	None

Medline (Ovid) search terms

1.	exp Borrelia Infections/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodid or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissetii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter/
13.	editorial/
14.	news/
15.	exp historical article/
16.	Anecdotes as Topic/
17.	comment/
18.	(letter or comment*).ti.
19.	or/12-18
20.	randomized controlled trial/ or random*.ti,ab.

21.	19 not 20
22.	animals/ not humans/
23.	exp Animals, Laboratory/
24.	exp Animal Experimentation/
25.	exp Models, Animal/
26.	exp Rodentia/
27.	(rat or rats or mouse or mice).ti.
28.	or/21-27
29.	11 not 28
30.	limit 29 to English language

1

Embase (Ovid) search terms

1.	exp Borrelia Infection/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter.pt. or letter/
13.	note.pt.
14.	editorial.pt.
15.	(letter or comment*).ti.
16.	or/12-15
17.	randomized controlled trial/ or random*.ti,ab.
18.	16 not 17
19.	animal/ not human/
20.	Nonhuman/
21.	exp Animal Experiment/
22.	exp Experimental animal/
23.	Animal model/
24.	exp Rodent/
25.	(rat or rats or mouse or mice).ti.
26.	or/18-25
27.	11 not 26
28.	limit 27 to English language

2

Cochrane Library (Wiley) search terms

1.	MeSH descriptor: [Borrelia Infections] explode all trees
2.	MeSH descriptor: [Lyme Disease] explode all trees
3.	MeSH descriptor: [Erythema Chronicum Migrans] explode all trees
4.	(erythema near/3 migrans):ti,ab
5.	lyme*:ti,ab

6.	(tick* near/2 (bite* or bitten or biting or borne)):ti,ab
7.	acrodermatitis chronica atrophicans:ti,ab
8.	MeSH descriptor: [Ixodidae] explode all trees
9.	(borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or ixodid or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti):ti,ab
10.	(granulocytic anaplasmosis or babesia or babesiosis):ti,ab
11.	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10

1 B.2 Health Economics literature search strategy

2 Health economic evidence was identified by conducting a broad search relating to Lyme
 3 disease population in NHS Economic Evaluation Database (NHS EED – this ceased to
 4 be updated after March 2015) and the Health Technology Assessment database (HTA)
 5 with no date restrictions. NHS EED and HTA databases are hosted by the Centre for
 6 Research and Dissemination (CRD). Additional searches were run on Medline and
 7 Embase for health economics, economic modelling and quality of life studies.

8 **Table 10: Database date parameters and filters used**

Database	Dates searched	Search filter used
Medline	1946 – 03 July 2017	Exclusions Health economics studies Health economics modelling studies Quality of life studies
Embase	1974 – 03 July 2017	Exclusions Health economics studies Health economics modelling studies Quality of life studies
Centre for Research and Dissemination (CRD)	HTA - Inception – 03 July 2017 NHSEED - Inception to March 2015	None

9 **Medline (Ovid) search terms**

1.	exp Borrelia Infections/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodid or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter/
13.	editorial/
14.	news/

15.	exp historical article/
16.	Anecdotes as Topic/
17.	comment/
18.	(letter or comment*).ti.
19.	or/12-18
20.	randomized controlled trial/ or random*.ti,ab.
21.	19 not 20
22.	animals/ not humans/
23.	exp Animals, Laboratory/
24.	exp Animal Experimentation/
25.	exp Models, Animal/
26.	exp Rodentia/
27.	(rat or rats or mouse or mice).ti.
28.	or/21-27
29.	11 not 28
30.	limit 29 to English language
31.	Economics/
32.	Value of life/
33.	exp "Costs and Cost Analysis"/
34.	exp Economics, Hospital/
35.	exp Economics, Medical/
36.	Economics, Nursing/
37.	Economics, Pharmaceutical/
38.	exp "Fees and Charges"/
39.	exp Budgets/
40.	budget*.ti,ab.
41.	cost*.ti.
42.	(economic* or pharmaco?economic*).ti.
43.	(price* or pricing*).ti,ab.
44.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
45.	(financ* or fee or fees).ti,ab.
46.	(value adj2 (money or monetary)).ti,ab.
47.	or/31-46
48.	exp models, economic/
49.	*Models, Theoretical/
50.	*Models, Organizational/
51.	markov chains/
52.	monte carlo method/
53.	exp Decision Theory/
54.	(markov* or monte carlo).ti,ab.
55.	econom* model*.ti,ab.
56.	(decision* adj2 (tree* or analy* or model*)).ti,ab.

57.	or/48-56
58.	quality-adjusted life years/
59.	sickness impact profile/
60.	(quality adj2 (wellbeing or well being)).ti,ab.
61.	sickness impact profile.ti,ab.
62.	disability adjusted life.ti,ab.
63.	(qal* or qtime* or qwb* or daly*).ti,ab.
64.	(euroqol* or eq5d* or eq 5*).ti,ab.
65.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
66.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
67.	(hui or hui1 or hui2 or hui3).ti,ab.
68.	(health* year* equivalent* or hye or hyes).ti,ab.
69.	discrete choice*.ti,ab.
70.	rosser.ti,ab.
71.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
72.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
73.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
74.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
75.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
76.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
77.	or/58-76
78.	30 and 47
79.	30 and 57
80.	30 and 77

1

Embase (Ovid) search terms

1.	exp Borrelia Infection/
2.	exp Lyme disease/
3.	Erythema Chronicum Migrans/
4.	(erythema adj3 migrans).ti,ab.
5.	lyme*.ti,ab.
6.	(tick* adj2 (bite* or bitten or biting or borne)).ti,ab.
7.	acrodermatitis chronica atrophicans.ti,ab.
8.	exp Ixodidae/
9.	(borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissettii or b valaisiana or b microti).ti,ab.
10.	(granulocytic anaplasmosis or babesia or babesiosis).ti,ab.
11.	or/1-10
12.	letter.pt. or letter/
13.	note.pt.
14.	editorial.pt.
15.	Case report/ or Case study/
16.	(letter or comment*).ti.

17.	or/12-16
18.	randomized controlled trial/ or random*.ti,ab.
19.	17 not 18
20.	animal/ not human/
21.	Nonhuman/
22.	exp Animal Experiment/
23.	exp Experimental animal/
24.	Animal model/
25.	exp Rodent/
26.	(rat or rats or mouse or mice).ti.
27.	or/19-26
28.	11 not 27
29.	limit 28 to English language
30.	health economics/
31.	exp economic evaluation/
32.	exp health care cost/
33.	exp fee/
34.	budget/
35.	funding/
36.	budget*.ti,ab.
37.	cost*.ti.
38.	(economic* or pharmaco?economic*).ti.
39.	(price* or pricing*).ti,ab.
40.	(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.
41.	(financ* or fee or fees).ti,ab.
42.	(value adj2 (money or monetary)).ti,ab.
43.	or/30-42
44.	statistical model/
45.	exp economic aspect/
46.	44 and 45
47.	*theoretical model/
48.	*nonbiological model/
49.	stochastic model/
50.	decision theory/
51.	decision tree/
52.	monte carlo method/
53.	(markov* or monte carlo).ti,ab.
54.	econom* model*.ti,ab.
55.	(decision* adj2 (tree* or analy* or model*)).ti,ab.
56.	or/46-55
57.	quality adjusted life year/
58.	"quality of life index"/

59.	short form 12/ or short form 20/ or short form 36/ or short form 8/
60.	sickness impact profile/
61.	(quality adj2 (wellbeing or well being)).ti,ab.
62.	sickness impact profile.ti,ab.
63.	disability adjusted life.ti,ab.
64.	(qal* or qtime* or qwb* or daly*).ti,ab.
65.	(euroqol* or eq5d* or eq 5*).ti,ab.
66.	(qol* or hql* or hqol* or h qol* or hrqol* or hr qol*).ti,ab.
67.	(health utility* or utility score* or disutilit* or utility value*).ti,ab.
68.	(hui or hui1 or hui2 or hui3).ti,ab.
69.	(health* year* equivalent* or hye or hyes).ti,ab.
70.	discrete choice*.ti,ab.
71.	rosser.ti,ab.
72.	(willingness to pay or time tradeoff or time trade off or tto or standard gamble*).ti,ab.
73.	(sf36* or sf 36* or short form 36* or shortform 36* or shortform36*).ti,ab.
74.	(sf20 or sf 20 or short form 20 or shortform 20 or shortform20).ti,ab.
75.	(sf12* or sf 12* or short form 12* or shortform 12* or shortform12*).ti,ab.
76.	(sf8* or sf 8* or short form 8* or shortform 8* or shortform8*).ti,ab.
77.	(sf6* or sf 6* or short form 6* or shortform 6* or shortform6*).ti,ab.
78.	or/57-77
79.	29 and 43
80.	29 and 56
81.	29 and 78

1

NHS EED and HTA (CRD) search terms


1.	MeSH DESCRIPTOR Borrelia Infections EXPLODE ALL TREES IN NHSEED,HTA
2.	MeSH DESCRIPTOR Erythema Chronicum Migrans EXPLODE ALL TREES IN NHSEED,HTA
3.	((erythema adj3 migrans)) IN NHSEED, HTA
4.	(lyme*) IN NHSEED, HTA
5.	((tick* adj2 (bite* or bitten or biting or borne))) IN NHSEED, HTA
6.	(acrodermatitis chronica atrophicans) IN NHSEED, HTA
7.	MeSH DESCRIPTOR Ixodidae EXPLODE ALL TREES IN NHSEED,HTA
8.	((borreliosis or borrelia* or neuroborreliosis or ixodidae or ixodes or b burgdorferi or b afzelii or b garinii or b bissetii or b valaisiana or b microti)) IN NHSEED, HTA
9.	((granulocytic anaplasmosis or babesia or babesiosis)) IN NHSEED, HTA
10.	MeSH DESCRIPTOR Lyme Disease EXPLODE ALL TREES IN NHSEED,HTA
11.	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10

2

1

Appendix C: Clinical evidence selection

Figure 1: Flow chart of clinical study selection for the review of diagnostic accuracy of signs and symptoms



2

3

Appendix D: Clinical evidence tables

Reference	Aucott 2009 ⁵
Study type	Cohort study
Study methodology	Data source: people presenting for possible early Lyme disease to a community-based Lyme disease referral practice Recruitment: consecutive
Number of patients	n=165
Patient characteristics	Age: not reported Gender (male to female ratio): not reported Family origin: not reported Setting: community-based Lyme disease referral practice Country: USA Inclusion criteria: all people referred with acute symptoms ≤12 weeks of duration Exclusion criteria: not reported Time from onset of symptoms to evaluation: ≤12 weeks
Target condition(s)	Lyme disease
Index test(s) and reference standard	Index tests EM Reference standard

Reference	Aucott 2009 ⁵			
	CDC case definition confirmed/probable			
	Time between measurement of index test and reference standard: not reported			
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	88	0	88
	Index test -	13	64	77
	Total	101	64	165
Statistical measures	Index test: EM Sensitivity 0.87 Specificity 1.00 PPV 1.00 NPV 0.83			
Source of funding	Not reported			
Limitations	Risk of bias: index test, reference standard Indirectness: none			
Comments				

Reference	Avery 2005 ⁶
Study type	Cohort study
Study methodology	Data source: children presenting to hospital with Lyme serology and Lyme CSF-PCR performed during the same hospital encounter Recruitment: consecutive
Number of patients	n=108
Patient characteristics	Age, mean (range): Lyme meningitis 9 years (2.7-13), aseptic meningitis 9.6 years (3.1-17.8) Gender (male to female ratio): Lyme meningitis 30% female, aseptic meningitis 31% female Family origin: Lyme meningitis 95% White, aseptic meningitis 68% White Setting: tertiary care children's hospital Country: USA Inclusion criteria: Lyme serology and Lyme CSF-PCR performed during the same hospital encounter, documented meningitis (CSF white blood cell count >8mm ³) Exclusion criteria: past history of Lyme meningitis, people being evaluated for an ongoing chronic neurological condition, traumatic lumbar puncture, positive CSF Gram stain for bacteria Time from onset of symptoms to evaluation: not reported
Target condition(s)	Lyme disease
Index test(s) and reference standard	Index tests EM Reference standard CDC criteria (EM or positive serology including Western blot confirmation) Time between measurement of index test and reference standard: not reported

Reference	Avery 2005 ⁶			
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	12	0	12
	Index test -	8	88	96
	Total	20	88	108
Statistical measures	Index test: EM Sensitivity 0.60 Specificity 1.00 PPV 1.00 NPV 0.92			
Source of funding	Not reported			
Limitations	Risk of bias: index test, reference standard Indirectness: none			
Comments	EM formed part of the reference standard			

Reference	Engervall 1995 ¹⁷
Study type	Cohort study
Study methodology	Data source: people with acute peripheral facial palsy presenting to 10 Swedish ear, nose and throat clinics Recruitment: consecutive
Number of patients	n=446
Patient characteristics	Age, median (range): people with borreliosis 38 years (4-82), no <i>Borrelia</i> infection 49 years (3-88) Gender (male to female ratio): not reported Family origin: not reported Setting: 10 ear, nose and throat clinics Country: Sweden Inclusion criteria: acute peripheral facial palsy Exclusion criteria: palsy of known aetiology such as trauma, tumour, herpes zoster infection or otitis media, hospitalised people with meningitis in whom facial palsy occurred as a secondary sign Time from onset of symptoms to evaluation: not reported
Target condition(s)	Lyme disease
Index test(s) and reference standard	Index tests Complete facial palsy Reference standard One or more of the following: serum antibody titres >1,000 in IgG ELISA or >1,500 in IgM ELISA, serum antibody titres of 500-1,000 in IgG ELISA and 800-1,500 in IgM ELISA if at least 2-fold increase in titres between 2 examinations, CSF <i>Borrelia</i> antibody titres >8 in IgG ELISA or >10 in IgM ELISA, recent history of presence of typical <i>Borrelia</i> skin manifestations

Reference	Engervall 1995 ¹⁷			
	Time between measurement of index test and reference standard: not reported			
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	5	115	120
	Index test -	20	259	279
	Total	25	374	399
Statistical measures	Index test: Complete facial palsy Sensitivity 0.20 Specificity 0.69 PPV 0.04 NPV 0.93			
Source of funding	Not reported			
Limitations	Risk of bias: index test, reference standard, flow and timing Indirectness: none			
Comments	Index test was complete facial palsy rather than presence/absence of facial palsy. 423 adults, 23 children			

Reference	Lipsker 2001³⁴			
Study type	Cohort study			
Study methodology	Data source: adults examined for suspected Lyme borreliosis at 1 hospital in France Recruitment: consecutive			
Number of patients	n=132			
Patient characteristics	Age, mean (range): 54 years (15-92) Gender (male to female ratio): 62/70 Family origin: White Setting: 1 hospital (people monitored in the dermatology, infectious diseases, rheumatology, neurology, internal medicine rehabilitation, cardiology, chest diseases and surgery departments) Country: France Inclusion criteria: US epidemiological case definitions for Lyme borreliosis Exclusion criteria: not reported Time from onset of symptoms to evaluation: not clearly reported			
Target condition(s)	Lyme disease			
Index test(s) and reference standard	Index tests EM Reference standard Culture or PCR Time between measurement of index test and reference standard: not reported			
2x2 table		Reference standard	Reference standard –	Total

Reference	Lipsker 2001 ³⁴			
		+		
	Index test +	5	4	9
	Index test -	5	27	32
	Total	10	31	41
Statistical measures	Index test: EM Sensitivity 0.50 Specificity 0.87 PPV 0.56 NPV 0.84			
Source of funding	Not reported			
Limitations	Risk of bias: index test, reference standard, flow and timing Indirectness: none			
Comments	All 132 people had a clinical diagnosis of Lyme disease according to US epidemiological case definitions for Lyme borreliosis, 41 of these had the culture/PCR testing			

Reference	Nadelman 1990 ³⁷
Study type	Cohort study
Study methodology	Data source: people who had an illness compatible with Lyme disease Recruitment: not clearly reported
Number of patients	n=104
Patient characteristics	Age, range: culture positive people 16-63 years, culture negative people not reported Gender (male to female ratio): culture positive people 1/6, culture negative people not reported Family origin: not reported Setting: not reported

Reference	Nadelman 1990 ³⁷			
	Country: USA			
	Inclusion criteria: not reported Exclusion criteria: not reported			
	Time from onset of symptoms to evaluation, range: culture positive people 3-14 days, culture negative people not reported			
Target condition(s)	Lyme disease			
Index test(s) and reference standard	Index tests EM Facial palsy Reference standard Culture from blood samples Time between measurement of index test and reference standard: not reported			
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	4	19	23
	Index test -	3	78	81
	Total	7	97	104
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	2	4	6
	Index test -	5	93	98
	Total	7	97	104
Statistical measures	Index test: EM Sensitivity 0.57 Specificity 0.80			

Reference	Nadelman 1990 ³⁷
	PPV 0.17 NPV 0.96 Index test: Facial palsy Sensitivity 0.29 Specificity 0.96 PPV 0.33 NPV 0.95
Source of funding	National Institutes of Allergy and Infectious Diseases and Westchester Health Fund
Limitations	Risk of bias: people selection, index test, reference standard Indirectness: none
Comments	

Reference	Ogrinc 2008 ⁴¹
Study type	Cohort study
Study methodology	Data source: people with suspected Lyme disease at outpatient's clinic Recruitment: consecutive
Number of patients	n=339
Patient characteristics	Age, median (range): 53 years (15-81) Gender (male to female ratio): 154/185 Family origin: not reported Setting: outpatient's clinic Country: Slovenia

Reference	Ogrinc 2008 ⁴¹			
	Inclusion criteria: suspected Lyme disease, aged >15 years Exclusion criteria: current erythema migrans Time from onset of symptoms to evaluation (median, range): 9.5 months (1-480)			
Target condition(s)	Lyme disease			
Index test(s) and reference standard	Index tests Cranial nerve involvement Reference standard serological evidence of Lyme disease: serum dilutions of 1:256 or higher interpreted as positive Time between measurement of index test and reference standard: not reported			
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	0	4	4
	Index test -	72	202	274
	Total	72	206	278
Statistical measures	Index test: cranial nerve involvement Sensitivity 0.00 Specificity 0.98 PPV 0.00 NPV 0.74			
Source of funding	Not reported			
Limitations	Risk of bias: index test, reference standard Indirectness: cranial nerve involvement used as index test rather than facial palsy			
Comments	Disease controls; exclusion of people with current erythema migrans; 30.1% of people had already been treated when they received the evaluation			

Reference	Peltomaa 1998 ⁴³
Study type	Cohort study
Study methodology	Data source: paediatric cases of acute peripheral facial palsy referred to the otorhinolaryngological outpatient department of 1 hospital Recruitment: consecutive
Number of patients	n=49
Patient characteristics	Age, mean: 9.1 years Gender (male to female ratio): 21/28 Family origin: not reported Setting: otorhinolaryngological outpatient department of 1 hospital Country: Finland Inclusion criteria: not reported Exclusion criteria: not reported Time from onset of symptoms to evaluation: not clearly reported
Target condition(s)	Lyme disease
Index test(s) and reference standard	Index tests EM Reference standard At least 1 of the following: positive levels of serum/CSF antibodies against <i>B. burgdorferi</i> , EM in the history of the person or concomitantly with facial palsy, positive PCR test Time between measurement of index test and reference standard: not reported

Reference	Peltomaa 1998 ⁴³			
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	10	0	10
	Index test -	7	32	39
	Total	17	32	49
Statistical measures	Index test: EM Sensitivity 0.59 Specificity 1.00 PPV 1.00 NPV 0.82			
Source of funding	Paulo Foundation, University Hospital of Helsinki and Clinical Research Institute of the University Central Hospital of Helsinki			
Limitations	Risk of bias: index test, reference standard, Indirectness: none			
Comments	All people had facial palsy. EM (index test) formed part of the criteria for the reference standard			

Reference	Pikelj-Pecnik 2002 ⁴⁵
Study type	Case-control study
Study methodology	Data source: children with typical EM at the Department of Infectious Diseases at a medical centre in Slovenia and healthy children of comparable ages and gender distribution Recruitment: consecutive
Number of patients	n=147 patients, 148 controls
Patient characteristics	Age, mean (SE): patients 5.74 years (3.13), controls 5.68 (3.18) Gender (male to female ratio): 163/132 Family origin: not reported

Reference	Pikelj-Pecnik 2002 ⁴⁵				
	Setting: Department of Infectious Diseases at a medical centre Country: Slovenia Inclusion criteria: <15 years of age, typical EM (diagnosis established clinically according to modified CDC criteria) Exclusion criteria: not reported Time from onset of symptoms to evaluation, median (range): duration of single EM 4 days (0-40), duration of multiple EM 5 days (0-60)				
Target condition(s)	Lyme disease				
Index test(s) and reference standard	Index tests Arrhythmia Reference standard EM (diagnosis established clinically according to modified CDC criteria) Time between measurement of index test and reference standard: not reported				
2x2 table		Reference standard +	Reference standard -	Total	
	Index test +	8	31	39	
	Index test -	139	117	256	
	Total	147	148	295	
Statistical measures	Index test: Arrhythmia Sensitivity 0.05 Specificity 0.79 PPV 0.21 NPV 0.46				
Source of funding	Not reported				
Limitations	Risk of bias: reference standard				

Reference	Pikelj-Pecnik 2002⁴⁵
	Indirectness: none
Comments	

Reference	Sangha 1998⁶⁰
Study type	Case-control study
Study methodology	Data source: Adults who reported a previous diagnosis of Lyme disease or a history of a positive result on a serologic test for <i>B. burgdorferi</i> (cases) and adults who reported no history of Lyme disease, with or without symptoms suggestive of previous Lyme disease (controls) Recruitment: random sampling from participants surveyed (5 cases: 2 controls)
Number of patients	n=336
Patient characteristics	Age, mean: cases 47.8 years, controls 49.7 years Gender (male to female ratio): 173/163 Family origin: not reported Setting: Nantucket Island Country: USA Inclusion criteria: previous diagnosis of Lyme disease or a history of a positive result on a serologic test for <i>B. burgdorferi</i> , meeting CDC criteria (cases), no history of Lyme disease, with or without symptoms suggestive of previous Lyme disease (controls), complete data on medical history and a 12-lead electrocardiogram Exclusion criteria: no electrocardiogram or uninterpretable due to technical difficulties Time from onset of symptoms to evaluation (mean): 5.2 years
Target condition(s)	Lyme disease
Index test(s)	Index tests

Reference	Sangha 1998 ⁶⁰			
and reference standard	Bradycardia Tachycardia Nonsinus rhythm First-degree atrioventricular block Any bundle-branch block Reference standard CDC case definition: EM (>5cm) or laboratory confirmation of infection and at least 1 late manifestation Time between measurement of index test and reference standard: not reported			
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	9	3	12
	Index test -	167	157	324
	Total	176	160	336
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	0	0	0
	Index test -	176	160	336
	Total	176	160	336
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	2	5	7
	Index test -	174	155	329
	Total	176	160	336
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	17	8	25
	Index test -	159	152	311
	Total	176	160	336

Reference	Sangha 1998 ⁶⁰			
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	29	25	54
	Index test -	147	135	282
	Total	176	160	336
Statistical measures	Index test: Bradycardia			
	Sensitivity 0.05			
	Specificity 0.98			
	PPV 0.75			
	NPV 0.49			
	Index test: Tachycardia			
	Sensitivity 0.00			
	Specificity 1.00			
	PPV 0.00			
	NPV 0.48			
	Index test: Nonsinus rhythm			
	Sensitivity 0.01			
	Specificity 0.97			
	PPV 0.29			
	NPV 0.47			
	Index test: First-degree atrioventricular block			
	Sensitivity 0.10			
	Specificity 0.95			
	PPV 0.68			
	NPV 0.49			
	Index test: Any bundle-branch block			
	Sensitivity 0.16			

Reference	Sangha 1998⁶⁰
	Specificity 0.84 PPV 0.54 NPV 0.48
Source of funding	National Institutes of Health Grants, German Academic Exchange Service
Limitations	Risk of bias: patient selection, reference standard Indirectness: none
Comments	

Reference	Shah 2005⁶⁷
Study type	Cohort study
Study methodology	Data source: medical records of people who underwent testing for Lyme meningitis or enteroviral meningitis Recruitment: consecutive
Number of patients	n=175 Lyme disease (n=24), enteroviral disease (n=151)
Patient characteristics	Age, median (range): Lyme disease: 10.5 years (4.1-16.9); enteroviral: 5.5 years (0-17.2) Gender (male to female ratio): Lyme disease: 63% boys; enteroviral: 62% boys Family origin: not reported Setting: urban tertiary children's hospital Country: USA Inclusion criteria: serological evidence of Lyme disease, CSF pleocytosis, negative CSF bacterial culture, and absence of virus

Reference	Shah 2005 ⁶⁷				
	detectable by CSF culture or PCR Exclusion criteria: underlying immunodeficiency, ventricular shunt, isolation of fungi or pathogenic bacteria from cultures, lumbar puncture not performed during initial evaluation Time from onset of symptoms to evaluation: not reported				
Target condition(s)	Lyme disease				
Index test(s) and reference standard	Index tests Erythema migrans rash (by history or on examination) Facial palsy Reference standard serological evidence of Lyme disease, CSF pleocytosis, negative CSF bacterial culture, and absence of virus detectable by CSF culture or PCR Time between measurement of index test and reference standard: not reported				
2x2 table		Reference standard +	Reference standard -	Total	
	Index test +	6	0	6	
	Index test -	18	151	169	
	Total	24	151	175	
		Reference standard +	Reference standard -	Total	
	Index test +	7	0	7	
	Index test -	17	151	168	
	Total	24	151	175	
Statistical measures	Index test: EM Sensitivity 0.25 Specificity 1.00 PPV 1.00				

Reference	Shah 2005⁶⁷
	NPV 0.89 Index text: facial palsy Sensitivity 0.29 Specificity 1.00 PPV 1.00 NPV 0.90
Source of funding	Not reported
Limitations	Risk of bias: index test, reference standard Indirectness: none
Comments	Disease controls

Reference	Skogman 2008⁶⁹
Study type	Cohort/case-control study
Study methodology	Data source: children referred to 5 paediatric clinics in Sweden for evaluation of clinically suspected neuroborreliosis including a lumbar puncture (cases), random sample of Swedish population from the Swedish national register of statistics (controls) Recruitment: consecutive
Number of patients	n=354
Patient characteristics	Age, median (range): confirmed neuroborreliosis 6 years (1-14), possible neuroborreliosis 7 years (1-18), not determined 12 years (2-18), controls were matched for age Gender (male to female ratio): cases 88/89, controls matched for gender Family origin: not reported Setting: 5 paediatric clinics

Reference	Skogman 2008 ⁶⁹				
	Country: Sweden				
	Inclusion criteria: children referred for evaluation of clinically suspected neuroborreliosis including a lumbar puncture Exclusion criteria: enteroviral meningitis, Epstein Barr virus infection, rheumatoid arthritis, sarcoidosis, missing data, controls with former <i>Borrelia</i> infection				
	Time from onset of symptoms to evaluation: <1 week n=66, 1-4 weeks n=81, 1-2 months n=17, >2 months n=13				
Target condition(s)	Lyme disease				
Index test(s) and reference standard	Index tests Facial palsy EM or lymphocytoma Reference standard Confirmed: pleocytosis in CSF, <i>Borrelia</i> antibodies in CSF. Possible: pleocytosis in CSF, no <i>Borrelia</i> antibodies in CSF, may have <i>Borrelia</i> antibodies in serum. Not determined: no pleocytosis in CSF, no <i>Borrelia</i> antibodies in CSF, may have antibodies in serum Time between measurement of index test and reference standard: not reported				
2x2 table		Reference standard +	Reference standard -	Total	Disease controls (neuroborreliosis not determined)
	Index test +	43	20	63	
	Index test -	29	39	68	
	Total	72	59	131	
2x2 table		Reference standard +	Reference standard -	Total	Healthy controls (6 month follow up)
	Index test +	43	0	43	
	Index test -	29	174	203	
	Total	72	174	246	
2x2 table		Reference standard +	Reference standard -	Total	Disease controls (neuroborreliosis not determined)
	Index test +	13	7	20	

Reference	Skogman 2008 ⁶⁹			
	Index test –	59	52	111
	Total	72	59	131
Statistical measures	<p>Index test: Facial palsy (disease controls) Sensitivity 0.60 Specificity 0.66 PPV 0.68 NPV 0.57</p> <p>Index test: Facial palsy (healthy controls) Sensitivity 0.60 Specificity 1.00 PPV 1.00 NPV 0.86</p> <p>Index test: EM or lymphocytoma (disease controls) Sensitivity 0.18 Specificity 0.88 PPV 0.65 NPV 0.47</p>			
Source of funding	The Health Research Council in the South East of Sweden, The County Council on Ostergotland, The Centre for Clinical Research in Dalarna, The Lions Foundation and The Samariten Foundation			
Limitations	Risk of bias: people selection, index test, reference standard Indirectness: none			
Comments	82 additional children evaluated for neuroborreliosis during the same period but not asked to participate – no explanation given. People categorised as ‘possible neuroborreliosis’ not included in the analysis; ‘not determined’ used as disease controls.			

Reference	Skogman 2015 ⁷⁰			
Study type	Cohort/case control study			
Study methodology	Data source: children being evaluated for neuroborreliosis and children being evaluated and diagnosed with other infectious immunological and neurological diseases at 7 paediatric clinics in Sweden Recruitment: consecutive			
Number of patients	n=239			
Patient characteristics	Age, median (range): children evaluated for Lyme disease 10 years (1-19), controls 10 years (0-19) Gender (male to female ratio): 108/131 Family origin: not reported Setting: 7 paediatric clinics Country: Sweden Inclusion criteria: not reported Exclusion criteria: missing data Time from onset of symptoms to evaluation: not reported			
Target condition(s)	Lyme disease			
Index test(s) and reference standard	Index tests NeBoP score (3 or more of the following: facial palsy, fever, fatigue, EM/lymphocytoma, pleocytosis in CSF) Reference standard European guidelines: definite and possible neuroborreliosis based on neurological symptoms and laboratory findings in CSF Time between measurement of index test and reference standard: not reported			
2x2 table		Reference standard	Reference standard –	Total

Reference	Skogman 2015 ⁷⁰		
		+	
	Index test +	75	15
	Index test -	8	141
	Total	83	156
Statistical measures	Index test: NeBoP score Sensitivity 0.90 Specificity 0.90 PPV 0.83 NPV 0.95		
Source of funding	Not reported		
Limitations	Risk of bias: index test, reference standard Indirectness: index test		
Comments	Calculations based on 'definite' and 'possible' Lyme neuroborreliosis as people and 'non-Lyme neuroborreliosis' and 'controls' as controls 7		

Reference	Sundin 2012 ⁷⁶
Study type	Cohort study
Study methodology	Data source: children with neurological complaints at the paediatric emergency department of a children's hospital in Sweden Recruitment: consecutive
Number of patients	n=124
Patient characteristics	Age, median (range): Neuroborreliosis 6.7 years (2-15), TBE8.7 years (3-17), no tick-borne CNS infection 9 years (1-17) Gender (male to female ratio): not reported Family origin: not reported Setting: paediatric emergency department in a children's hospital (primary care unit and referrals from GPs)

Reference	Sundin 2012 ⁷⁶				
	Country: Sweden Inclusion criteria: altered sensorium, back pain, behavioural changes, confusion, focal neurological signs, headache, motor dysfunction, neck stiffness, seizures and vertigo/balance problems Exclusion criteria: recent head injury, known convulsive disorder with suboptimal treatment and infancy (<12 months of age) Time from onset of symptoms to evaluation: not reported				
Target condition(s)	Lyme disease				
Index test(s) and reference standard	Index tests Cranial nerve facial palsy Reference standard Positive anti- <i>Borrelia</i> IgM or an increased titre (≥ 4 -fold) of anti- <i>Borrelia</i> IgG between acute and convalescent samples Time between measurement of index test and reference standard: not reported				
2x2 table		Reference standard +	Reference standard -	Total	Disease controls (tick-borne encephalitis)
	Index test +	9	0	9	
	Index test -	12	10	22	
	Total	21	10	31	
2x2 table		Reference standard +	Reference standard -	Total	Disease controls (other diagnoses)
	Index test +	9	9	18	
	Index test -	12	84	96	
	Total	21	93	114	
Statistical measures	Index test: Cranial nerve palsy (TBE controls) Sensitivity 0.43 Specificity 1.00 PPV 1.00				

Reference	Sundin 2012 ⁷⁶
	NPV 0.45 Index test: Cranial nerve palsy (other diagnoses controls) Sensitivity 0.43 Specificity 0.90 PPV 0.50 NPV 0.88
Source of funding	Karolinska Institutet, Stockholm County Council and the Swedish Association of Persons with Neurological Disabilities
Limitations	Risk of bias: index test, reference standard Indirectness: none
Comments	'Other diagnoses' group included 3 cutaneous borreliosis

Reference	Tjernberg 2011 ⁷⁹
Study type	Cohort study
Study methodology	Data source: people investigated for suspected Lyme neuroborreliosis Recruitment: not clearly reported
Number of patients	n=261
Patient characteristics	Age, range: 2-87 years Gender (male to female ratio): 157/104 Family origin: not reported Setting: Department of Clinical Microbiology Country: Sweden

Reference	Tjernberg 2011 ⁷⁹			
	Inclusion criteria: lumbar puncture performed because of suspected Lyme neuroborreliosis Exclusion criteria: incomplete CSF/serum sample material Time from onset of symptoms to evaluation, median (range): definite Lyme neuroborreliosis 3 weeks (0-32), non-Lyme neuroborreliosis 4 weeks (0-730)			
Target condition(s)	Lyme disease			
Index test(s) and reference standard	Index tests Cranial nerve palsy Reference standard European Federation of Neurological Societies guidelines (CSF anti- <i>Borrelia</i> anti-bodies and presence of pleocytosis) Time between measurement of index test and reference standard: not reported			
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	64	13	77
	Index test -	60	79	139
	Total	124	92	216
Statistical measures	Index test: Cranial nerve palsy Sensitivity 0.52 Specificity 0.86 PPV 0.83 NPV 0.57			
Source of funding	Not reported			
Limitations	Risk of bias: people selection, index test, reference standard Indirectness: population (adults and children)			
Comments	Definite Lyme neuroborreliosis and non-Lyme neuroborreliosis groups used in analysis, possible Lyme neuroborreliosis group excluded.			

Reference	Tveitnes 2012 ⁸⁰
Study type	Cohort study
Study methodology	Data source: children with CSF pleocytosis at the paediatric department of a hospital in Norway Recruitment: consecutive
Number of patients	n=211
Patient characteristics	Age, median (interquartile range): Lyme meningitis 6 years (5-8), bacterial meningitis 3 years (0-6), non-Lyme aseptic meningitis 7 years (3.5-9) Gender (male to female ratio): 107/98 Family origin: not reported Setting: paediatric department in a coastal Lyme disease endemic region Country: Norway Inclusion criteria: children with pleocytosis from 3 months of age up to their 14th birthday Exclusion criteria: non-infectious causes of CSF pleocytosis Time from onset of symptoms to evaluation (median, interquartile range): Lyme meningitis 5 days (2-14), bacterial meningitis 1 day (1-3), non-Lyme aseptic meningitis 3 days (1-7)
Target condition(s)	Lyme disease
Index test(s) and reference standard	Index tests EM Acute facial palsy Reference standard Confirmed Lyme meningitis: neurological symptoms suggestive of neuroborreliosis without other obvious reasons, intrathecal <i>B. burgdorferi</i> antibody production/ Probable Lyme meningitis: neurological symptoms suggestive of neuroborreliosis without other obvious reasons, <i>B. burgdorferi</i> antibody in serum or EM

Reference	Tveitnes 2012 ⁸⁰			
	Time between measurement of index test and reference standard: not reported			
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	33	0	33
	Index test -	109	63	172
	Total	142	63	205
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	104	3	107
	Index test -	38	60	98
	Total	142	63	205
Statistical measures	Index test: EM Sensitivity 0.23 Specificity 1.00 PPV 1.00 NPV 0.37 Index test: Acute facial palsy Sensitivity 0.73 Specificity 0.95 PPV 0.97 NPV 0.61			
Source of funding	The Western Norway Regional Health Authority			
Limitations	Risk of bias: index test, reference standard Indirectness: none			
Comments	People group included 91 with confirmed and 51 with probable Lyme disease. Six from the disease control group were not included in the analysis due to intracranial infection complicating upper airway infection (3), infection in a ventriculo-peritoneal shunt (1), antibiotics before lumbar puncture (1) and tuberculous meningitis (1).			

Reference	Waespe 2010 ⁸⁶
Study type	Cohort study
Study methodology	Data source: children hospitalised with clinical signs of aseptic meningitis or peripheral facial nerve palsy at a children's hospital in Switzerland Recruitment: consecutive
Number of patients	n=181
Patient characteristics	Age, range: 20 months to 16 years Gender (male to female ratio): 118/63 Family origin: not reported Setting: 1 children's hospital Country: Switzerland Inclusion criteria: ≥12 months of age, hospitalised with clinical signs of aseptic meningitis or peripheral facial nerve palsy Exclusion criteria: people with missing CSF sample results Time from onset of symptoms to evaluation, mean (interquartile range): people with neuroborreliosis 7.6 days (3-9)
Target condition(s)	Lyme disease
Index test(s) and reference standard	Index tests Peripheral facial nerve palsy Reference standard Evidence of intrathecal synthesis of <i>B. burgdorferi</i> antibodies in CSF (confirmed) or in serum or CSF, both confirmed by immunoblot (probable)

Reference	Waespe 2010 ⁸⁶			
	Time between measurement of index test and reference standard: not reported			
2x2 table		Reference standard +	Reference standard -	Total
	Index test +	25	32	57
	Index test -	9	93	102
	Total	34	125	159
Statistical measures	Index test: Peripheral facial nerve palsy Sensitivity 0.74 Specificity 0.74 PPV 0.44 NPV 0.91			
Source of funding	Not reported			
Limitations	Risk of bias: index test, reference standard, flow and timing Indirectness: none			
Comments	Index test positive people were those with facial palsy and those with facial palsy plus aseptic meningitis. 159/181 people were tested for Lyme disease.			

Appendix E: Coupled sensitivity and specificity forest plots and sROC curves

E.1 Coupled sensitivity and specificity forest plots (adults)

E.1.1 Evidence from cohort studies

Figure 2: Sensitivity and specificity of Erythema migrans for diagnosing Lyme disease in adults






Figure 3: Sensitivity and specificity of facial palsy for diagnosing Lyme disease in adults




5

Figure 4: Sensitivity and specificity of complete facial palsy for diagnosing Lyme disease in adults




6

Figure 5: Sensitivity and specificity of cranial nerve involvement for diagnosing Lyme disease in adults




E.1.2 Evidence from case-control studies

Figure 6: Sensitivity and specificity of arrhythmia (bradycardia) for diagnosing Lyme disease in adults




1

Figure 7: Sensitivity and specificity of arrhythmia (tachycardia) for diagnosing Lyme disease in adults




2

Figure 8: Sensitivity and specificity of arrhythmia (non-sinus rhythm) for diagnosing Lyme disease in adults




3

Figure 9: Sensitivity and specificity of heart block (atrioventricular block) for diagnosing Lyme disease in adults



4

Figure 10: Sensitivity and specificity of heart block (any bundle-branch block) for diagnosing Lyme disease in adults



5 E.2 Coupled sensitivity and specificity forest plots (children)

6 E.2.1 Evidence from cohort studies

Figure 11: Sensitivity and specificity of Erythema migrans for diagnosing Lyme disease in children






Figure 12: Sensitivity and specificity of facial palsy for diagnosing Lyme disease in children




1

Figure 13: Sensitivity and specificity of facial palsy (TBE controls) for diagnosing Lyme disease in children



2

Figure 14: Sensitivity and specificity of NeBoP score for diagnosing Lyme disease in children



3 E.2.2 Evidence from case-control studies

Figure 15: Sensitivity and specificity of Erythema migrans and lymphocytoma for diagnosing Lyme disease in children






Figure 16: Sensitivity and specificity of facial palsy (disease controls) for diagnosing Lyme disease in children




4

Figure 17: Sensitivity and specificity of facial palsy (healthy controls) for diagnosing Lyme disease in children



5


Figure 18: Sensitivity and specificity of arrhythmia for diagnosing Lyme disease in children



6


1 E.3 ROC curves

Figure 19: sROC curve with pooled sensitivity and specificity of erythema migrans for diagnosing Lyme disease in adults (cohort studies)




2

Figure 20: sROC curve with pooled sensitivity and specificity of erythema migrans for diagnosing Lyme disease in children (cohort studies)



1
2

Figure 21: sROC curve with pooled sensitivity and specificity of facial palsy for diagnosing Lyme disease in children (cohort studies)



3


4 E.4 Area under the curve

No graphs.

1
2

Appendix F: Health economic evidence selection

Figure 22: Flow chart of economic study selection for the guideline



* Non-relevant population, intervention, comparison, design or setting; non-English language

3

Appendix G: Health economic evidence tables

None.

1 Appendix H: Excluded studies

2 H.1 Excluded clinical studies

3 **Table 11: Studies excluded from the clinical review**

Reference	Reason for exclusion
Afari 2016 ¹	Excluded due to an incorrect study design
Ahmed 2005 ²	Excluded due to an incorrect study design
Arnez 2003 ³	Excluded due to an incorrect population
Asbrink 1986 ⁴	Excluded due to an incorrect study design
Bartunek 1995 ⁷	Unable to obtain paper
Biese 2006 ⁸	Excluded due to an incorrect study design
Broekhuijsen-van Henten 2010 ⁹	Excluded due to an incorrect study design
Caruso 1985 ¹⁰	Excluded due to an incorrect study design
Coumou 2015 ¹¹	Excluded due to an incorrect analysis
Dillon 2010 ¹²	Excluded due to an incorrect study design
Dolbec 2010 ¹³	Excluded due to an incorrect study design
Doorey 1991 ¹⁴	Excluded due to an incorrect study design
Dunand 1998 ¹⁵	Excluded due to an incorrect study design
Earl 2010 ¹⁶	Excluded due to an incorrect study design
Esposito 2013 ¹⁸	Excluded due to an incorrect study design
Fahrer 1991 ¹⁹	Excluded due to an incorrect analysis
Feder 1995 ²⁰	Excluded due to an incorrect outcome
Felz 1999 ²¹	Excluded due to an incorrect study design
Gissler 2002 ²²	Excluded due to an incorrect abstract only
Goos 1971 ²³	Excluded due to an incorrect study design
Grandsaerd 2000 ²⁴	Excluded due to an incorrect study design
Halperin 1990 ²⁵	Excluded due to an incorrect study design
Hanner 1993 ²⁶	Excluded due to an incorrect study design
Holland 2004 ²⁷	Excluded due to an incorrect population
Hufschmidt 2009 ²⁸	Excluded due to an incorrect analysis
Jenke 2011 ²⁹	Excluded due to an incorrect study design
Keh 2012 ³⁰	Excluded due to an incorrect study design
Kimball 1989 ³¹	Excluded due to an incorrect study design
Kindler 2015 ³²	Excluded due to an incorrect population
Kindstrand 1997 ³³	Excluded due to an incorrect analysis
Lotric-Furlan 1999 ³⁵	Excluded due to an incorrect analysis
Malane 1991 ³⁶	Excluded due to an incorrect study design
Neubert 1986 ³⁹	Excluded due to an incorrect analysis
Nigrovic 2008 ⁴⁰	Excluded due to an incorrect analysis
Oymar 2009 ⁴²	Excluded due to an incorrect analysis
Petersen 1989 ⁴⁴	Excluded due to an incorrect analysis
Pohl-Koppe 1998 ⁴⁶	Excluded due to an incorrect study design
Puri 2014 ⁴⁷	Excluded due to an incorrect analysis
Qureshi 2002 ⁴⁸	Excluded due to an incorrect analysis

Reference	Reason for exclusion
Randazzo 1993 ⁴⁹	Excluded due to an incorrect study design
Ranki 1994 ⁵⁰	Excluded due to an incorrect analysis
Rattner 1948 ⁵¹	Excluded due to an incorrect study design
Rees 1994 ⁵²	Excluded due to an incorrect population
Reid 1998 ⁵³	Excluded due to an incorrect analysis
Richier 2013 ⁵⁴	Not in English
Rijkema 1997 ⁵⁵	Excluded due to an incorrect analysis
Rose 1991 ⁵⁸	Excluded due to an incorrect analysis
Rose 1994 ⁵⁷	Excluded due to an incorrect analysis
Rose 1994 ⁵⁶	Excluded due to an incorrect analysis
Ross 1989 ⁵⁹	Excluded due to an incorrect study design
Santino 2008 ⁶¹	Excluded due to an incorrect analysis
Schmidt 1995 ⁶²	Excluded due to an incorrect analysis
Schwartz 1993 ⁶³	Excluded due to an incorrect analysis
Scrimenti 1970 ⁶⁴	Excluded due to an incorrect study design
Seltzer 2000 ⁶⁵	Excluded due to an incorrect analysis
Seltzer 1996 ⁶⁶	Excluded due to an incorrect study design
Sigal 1990 ⁶⁸	Excluded due to an incorrect symptom
Smith 2002 ⁷¹	Excluded due to an incorrect analysis
Smouha 1997 ⁷²	Excluded due to an incorrect study design
Sood 1998 ⁷³	Excluded due to an incorrect study design
Steere 1993 ⁷⁴	Excluded due to an incorrect analysis
Steinberg 1996 ⁷⁵	Excluded due to an incorrect study design
Thompson 2009 ⁷⁷	Excluded due to an incorrect analysis
Tibbles 2007 ⁷⁸	Excluded due to an incorrect study design
Tveitnes 2015 ⁸¹	Excluded due to an incorrect analysis
Tveitnes 2007 ⁸²	Excluded due to an incorrect analysis
Vegsundvag 1993 ⁸³	Excluded due to an incorrect study design
Von Stedingk 1995 ⁸⁴	Excluded due to an incorrect analysis
Vrethem 2011 ⁸⁵	Excluded due to an incorrect analysis
Wackers Garritsen 1974 ⁸⁷	Excluded due to an incorrect study design
Weber 1986 ⁸⁸	Excluded due to an incorrect study design
Wetter 2011 ⁸⁹	Excluded due to an incorrect study design
Wienecke 1995 ⁹⁰	Excluded due to an incorrect analysis
Wise 1946 ⁹¹	Excluded due to an incorrect study design
Wolf 1991 ⁹²	Excluded due to an incorrect analysis
Wormser 2013 ⁹³	Excluded due to an incorrect analysis
Younger 2010 ⁹⁴	Excluded due to an incorrect study design
Zajkowska 2011 ⁹⁵	Excluded due to an incorrect study design

1 **H.2 Excluded health economic studies**

2 **Table 12: Studies excluded from the health economic review**

Reference	Reason for exclusion
None	

3